FINAL PROGRAM

5th Asian and Oceanian Parkinson’s Disease and Movement Disorders Congress

March 11–13, 2016 • MANILA, PHILIPPINES

www.aopmc2016.org
Treatment of focal spasticity, including arm symptoms associated with focal spasticity in conjunction with physiotherapy in adults. Dynamic equinus foot deformity due to spasticity in ambulant paediatric cerebral palsy patients, 2 years of age or older. Spasmodic torticollis, blepharospasm and hemifacial spasm in adults.

CLOSTRIDIUM BOTULINUM TYPE A TOXIN

Dysport®

Be you
Become a Member of MDS

Meet & Collaborate with over 6,000 colleagues across the globe and become a part of a Medical and Educational community dedicated to disseminating knowledge and promoting research to advance the field of Movement Disorders.

**MDS Members receive the following benefits:**

- **Peer Reviewed Journals:** Movement Disorders and Movement Disorders – Clinical Practice
- **Quarterly Newsletter:** Moving Along
- **Reduced Course Registration Rates**
- **Online Resources:** CME Activities; Streaming Content; Training Videos; and a Video Library with over 1,800 searchable videos

**NON-MEMBER OPPORTUNITIES**

Free One-Year Trial Membership
Open to Eligible AOPMC Delegates

**ASSOCIATE MEMBERSHIP**

Non-members attending the AOPMC have the opportunity to receive membership with MDS absolutely free for a year. Eligible participants will be invited by e-mail by June to apply for free Associate membership. Interested individuals are encouraged to apply online within 30 days of contact.

Learn more at [www.movementdisorders.org/membership.htm](http://www.movementdisorders.org/membership.htm) or contact the International Secretariat:

MDS International Secretariat
555 E. Wells Street, Suite 1100
Milwaukee, WI 53202 USA
Tel: +1 414-276-2145
Fax: +1 414-276-3349
E-mail: info@movementdisorders.org
# Table of Contents

- Welcome .................................................................................................................. 5
- About MDS .................................................................................................................. 6
- About MDS-AOS .......................................................................................................... 8
- AOPMC Organizing Committee .................................................................................. 9
- AOPMC Meeting Information A-Z .............................................................................. 10
- Venue Floor Plan ......................................................................................................... 12
- Award Information ....................................................................................................... 13
- AOPMC Schedule-at-a-Glance ................................................................................... 15

## Scientific Program

- Friday, March 11, 2016 ............................................................................................... 16
- Saturday, March 12, 2016 ......................................................................................... 18
- Sunday, March 13, 2016 ............................................................................................. 23

- Faculty Listing .............................................................................................................. 27
- Poster Session Schedule ............................................................................................. 28
- Guided Poster Tours ...................................................................................................... 29
- Abstract Listing by Topic .............................................................................................. 33
- Late-Breaking Abstracts ................................................................................................. 44
- Exhibit Area Floor Plans .............................................................................................. 45
- Acknowledgements of Support .................................................................................... 47
- MDS Education Information ......................................................................................... 48
- Certificate of Attendance .............................................................................................. 51
Dear Colleagues,

On behalf of the International Parkinson and Movement Disorder Society – Asian and Oceanian Section (MDS-AOS) and the Movement Disorder Society of the Philippines (MDSP), we would like to formally welcome you to Manila, Philippines for the 5th Asian and Oceanian Parkinson’s Disease and Movement Disorders Congress (AOPMC)!

We would like to express our gratitude to the AOPMC Scientific Program Committee for the hard work and coordination of this diverse program. There are over 70 world renowned experts in the field of Movement Disorders on the Scientific Program showcasing the faculty from the AOS region. We would also like to thank the AOPMC Local Organizing Committee who provided local support to the MDS International Secretariat during the entire planning process.

While in Manila, we hope that you not only allot time in your schedule to participate in our detailed program, visit the exhibit and poster areas and attend the social events, but also get a chance to see the signs and sounds of what makes Manila such a unique destination.

We are pleased to see you in Manila for the 5th AOPMC and thank you for taking the opportunity to be a part of this educational experience.

As we warmly welcome you to the Philippines, we say “Mabuhay” to us all!

With kind regards,

Raymond Rosales
Chair,
5th AOPMC
Scientific Program Committee

Roland Dominic Jamora
Chair,
5th AOPMC
Local Organizing Committee

Nobutaka Hattori
Chair,
MDS-AOS
2015-2017
The International Parkinson and Movement Disorder Society (MDS) is a professional society of clinicians, scientists, and other healthcare professionals who are interested in Parkinson’s disease, related neurodegenerative and neurodevelopmental disorders, hyperkinetic movement disorders, and abnormalities in muscle tone and motor control. The spectrum of clinical disorders represented by the Society includes, but is not limited to:

- Ataxia
- Chorea
- Dystonia
- Gait disorders
- Huntington’s disease
- Myoclonus and startle
- Parkinson’s disease and parkinsonism
- Restless legs syndrome
- Spasticity
- Stiff person syndrome
- Tardive dyskinesia
- Tics and Tourette syndrome
- Tremor and essential tremor

In recent years, there has been tremendous growth in new diagnostic information, pharmacological and neurosurgical treatments for Movement Disorders, as well as a greater understanding of impaired motor control function. MDS offers you and your patients an essential link to this knowledge.

In 1985, The Movement Disorder Society was founded on the initiative of Professors Stanley Fahn and C. David Marsden, whose leadership and vision guided the expansion of clinical expertise and research in this field. This not-for-profit organization merged in 1992 with the International Medical Society for Motor Disturbances. Publication of the journal Movement Disorders began in 1986, and the first International Congress was held in 1990.

In 2013, The Movement Disorder Society officially changed its name to the International Parkinson and Movement Disorder Society, in order to recognize the growing importance of Parkinson’s disease care and research within the field of Movement Disorders.

About MDS

Purpose, Mission And Goals

Purpose:
The objective and mission of the Society shall be to advance the neurological sciences pertaining to Movement Disorders; to improve the diagnosis and treatment of patients; to operate exclusively for scientific, scholarly and educational purposes; to encourage research; to provide forums, such as medical journals, scientific symposia and International Congresses, for sharing ideas and for advancing the related clinical and scientific disciplines; to encourage interest and participation in the activities of the Society among healthcare and allied professionals and scientists; and to collaborate with other related professional and lay organizations.

Mission and Goals:
To disseminate knowledge about movement disorders by:
• Providing educational programs for clinicians, scientists and the general public designed to advance scientific and clinical knowledge about movement disorders
• Sponsoring International Congresses and Symposia on movement disorders
• Collaborating with other international organizations and lay groups
• Publishing journals, videotapes and other collateral materials committed to high scientific standards and peer review

To promote research into causes, prevention and treatment of movement disorders by:
• Using the Society’s influence and resources to enhance support for research
• Facilitating the dissemination of information about research
• Encouraging the training of basic and clinical scientists in movement disorders and related disorders

For the purposes of favorably affecting the care of patients with movement disorders, the Society will provide expertise, advice and guidance to:
• Regulatory agencies to assist them in the approval process of safe and effective therapeutic interventions
• The public (media) and patient support groups by informing them of new research and therapeutic advances
• Governments to assist them in the development of policies that affect support of research and patient care
• Educational efforts to assist in developing standards of training in the specialty
About MDS


President
Oscar Gershanik, Argentina

President-Elect
Christopher Goetz, USA

Secretary
Claudia Trenkwalder, Germany

Secretary-Elect
Susan Fox, Canada

Treasurer
David John Burn, United Kingdom

Treasurer-Elect
Victor Fung, Australia

Past-President
Matthew Stern, USA

MDS International Executive Committee
Paolo Barone, Italy
Daniela Berg, Germany
Bastiaan Bloem, Netherlands
Carlos Cosentino, Peru
Beom Jeon, Korea
Jeffrey Kordower, USA
Michael Okun, USA
Mark Stacy, USA
Ryosuke Takahashi, Japan
Louis Tan, Singapore

Past-Presidents
2013-2015 Matthew Stern, USA
2011-2013 Günther Deuschl, Germany
2009-2011 Philip Thompson, Australia
2007-2009 Anthony Lang, Canada
2005-2006 Andrew Lees, United Kingdom
2003-2004 C. Warren Olanow, USA
2001-2002 Werner Poewe, Austria
1999-2000 Mark Hallett, USA
1997-1998 Eduardo Tolosa, Spain
1995-1996 Joseph Jankovic, USA
1991-1994 C. David Marsden, United Kingdom
1988-1991 Stanley Fahn, USA

International Medical Society for Motor Disturbances Past-Presidents
1993-1994 C. Warren Olanow, USA
1991-1992 Bastian Conrad, Germany
1989-1990 Mark Hallett, USA
1987-1988 Mario Manfredi, Italy
1985-1986 C. David Marsden, United Kingdom

MDS International Secretariat
International Parkinson and Movement Disorder Society
555 East Wells Street, Suite 1100
Milwaukee, WI 53202-3823 USA
Tel: +1 414-276-2145
Fax: +1 414-276-3349
info@movementdisorders.org
www.movementdisorders.org
MDS-AOS Officers

Chair
Nobutaka Hattori, Japan

Chair-Elect
Beom Jeon, Korea

Secretary
Raymond Rosales, Philippines

Secretary-Elect
Shen-Yang Lim, Malaysia

Treasurer
Carolyn Sue, Australia

Treasurer-Elect
Yasuyuki Okuma, Japan

Past-President
Louis Tan, Singapore

About MDS-AOS

MDS Asian and Oceanian Section
The mission of MDS-AOS is to represent and promote the International Parkinson and Movement Disorder Society (MDS) in Asia and Oceania. Membership of MDS-AOS is open to all members of MDS within the Asian and Oceanian region.

The Asian and Oceanian Section was formed in 2006 at the 10th International Congress of Parkinson’s Disease and Movement Disorders in Kyoto, Japan. The MDS-AOS aims to facilitate communication between clinicians and researchers in the region; disseminate updated knowledge about Movement Disorders; improve quality of life and independence of movement disorders patients and caregivers; and promote research in Movement Disorders within the region.

For further information on MDS-AOS or its educational opportunities, please visit www.movementdisorders.org/MDS-AOS.

MDS-AOS Executive Committee
Mandy Au-Yeung, Hong Kong
Jou-Hsien Chen, Taiwan
Vinay Goyal, India
Roland Dominic Jamora, Philippines
Hee Tae Kim, Korea
Thomas Kimber, Australia
Miho Murata, Japan
Hui Fang Shang, People’s Republic of China
Yih-Ru Wu, Taiwan
Baorong Zhang, People’s Republic of China

MDS-AOS Education Committee
Co-Chair: Shen-Yang Lim, Malaysia
Chair: Hui Fang Shang, People’s Republic of China
Jawad Bajwa, Saudi Arabia
Jae Woo Kim, Korea
Simon Lewis, Australia
Hideki Mochizuki, Japan
Pramod Pal, India
Thamrin Syamsudin, Indonesia
Win Min Thit, Myanmar
Qin Xiao, People’s Republic of China
AOPMC Organizing Committees

Oversight Committee
Chair: Nobutaka Hattori, Japan
Roongroj Bhidayasiri, Thailand
Cid Diesta, Philippines
Roland Dominic Jamora, Philippines
Raymond Rosales, Philippines
Carolyn Sue, Australia
Louis Tan, Singapore
Ruey-Meei Wu, Taiwan

Scientific Program Committee
Chair: Raymond Rosales, Philippines
Mandy Au-Yeung, Hong Kong
Jawad Bajwa, Saudi Arabia
Cid Diesta, Philippines
Hubert Fernandez, USA/Philippines
Roland Dominic Jamora, Philippines
Shen-Yang Lim, Malaysia
Carolyn Sue, Australia
Yoshikazu Ugawa, Japan
Yih-Ru Wu, Taiwan

Local Organizing Committee
Chair: Roland Dominic Jamora
Co-Chair: Cid Diesta
Lucy Kathrina Banta-Banzali
Donna Buhat
Crisceley Go
Arlene Ng
Jean-Quint Oropilla
Rafael Palacio
Anthony Piano
Rosalia Teleg

Honorary Advisor
Lillian Lee, Philippines

Video Tournament Committee
Donna Buhat, Philippines
Han-Lin Chiang, Taiwan
Thien Thien Lim, Malaysia
Zheyu Xu, Singapore
Abstracts
All accepted abstracts (including Late-Breaking) are presented as a poster at the 5th AOPMC. Authors are to be present at their poster from 11:30-12:30 on Saturday, March 12 and Sunday, March 13. All regular accepted abstracts are published as an online supplement to the Movement Disorders Journal. Additionally, select abstracts are presented in a Guided Poster Tour. Please visit www.aopmc2016.org for further publication information.

All registered AOPMC delegates will also receive the published abstracts on a USB, available for pickup in the registration area during regular Congress hours.

For further information regarding abstracts and poster presentation schedules, please see page 28.

Late-Breaking Abstracts
All accepted Late-Breaking Abstract posters are displayed in the Marriott Grand Ballroom, Ground Floor Foyer on Saturday and Sunday. These poster presentations will take place on Saturday, March 12 from 11:30 – 12:30. The Late-Breaking Abstracts will be available on the AOPMC website (www.aopmc2016.org) as of Friday, March 11.

For further information regarding Late-Breaking, abstracts and poster presentation schedules, please see page 44.

Badges
All AOPMC attendees will receive a name badge with their registration materials. Badges should be worn at all times as they are used to gain access into all AOPMC sessions and activities.

Certificate of Attendance
A certificate of attendance is available in the back of the AOPMC Final Program or at the registration desk.

Coffee Breaks
Coffee and tea will be available in Executive Room 7 and 9 and Ceremonial Hall, Ground Floor at the following times:

- Friday, March 11: 15:30 – 16:00
- Saturday, March 12: 9:30 – 10:00
- *The Saturday morning coffee break is sponsored by H. Lundbeck A/S*
- Saturday, March 12: 16:00 – 16:30
- Sunday, March 13: 9:30 – 10:00

Currency
The official currency of the 5th AOPMC is US Dollars and Philippine Pesos; no other currency will be accepted.

Evaluations
Please take time to complete the evaluation form provided at each session you attend. Your input and comments are essential in planning future educational programs for MDS.

Upon completion, evaluations may be returned to the session room attendants, or to the registration desk (located in the Box Office, Ground Floor).

Events
Opening Ceremony
Friday, March 11
Location: Ballroom CD, Second Floor
18:30 to 19:30

All AOPMC attendees are warmly invited to attend the Welcome Ceremony at the Marriott Grand Ballroom with a reception to follow. This event is open to all registered delegates.

_The MDS-AOS would like to acknowledge Boehringer Ingelheim for their support of the Opening Ceremony through an unrestricted grant._

AOPMC Video Tournament
Saturday, March 12
Location: Ballroom CD, Second Floor
18:30 – 20:30

Please join Masters of Ceremony Victor Fung and Janis Miyasaki as they host this interactive tournament which will challenge participants to improve diagnostic skills with unique and interesting cases. This event is open to all registered delegates.

Exhibition
Location: Executive Rooms 7 and 9 and Ceremonial Hall, Ground Floor

For more information, please refer to page 45.

- Friday, March 11: 13:00 – 20:00
- Saturday, March 12: 9:00 – 18:30
- Sunday, March 13: 9:00 – 16:30

Floor Plans of the Marriott Grand Ballroom
Please refer to page 12.
Guided Poster Tours
Guided Poster Tours will give small groups of delegates an opportunity to hear discussion by abstract authors on a select group of abstracts in several sub-categories led by members of the AOPMC faculty. There will be ten total Guided Poster Tours with five simultaneous tours per day during the regular poster sessions on Saturday, March 12 and Sunday, March 13. Anyone is welcome to attend; please meet at the first poster of the tour at the start time. Each tour will highlight exceptional posters. Please refer to page 29 for further Guided Poster Tour information and schedules.

The MDS-AOS would like to acknowledge Aguettant for their support of the Guided Poster Tours through an unrestricted grant.

Internet
Complimentary Wi-Fi will be available throughout the Marriott Grand Ballroom for all attendees.
Username: AOPMC2016
Password: AOPMC2016

Official Language
The official language of the AOPMC is English.

Registration Desk
Location: Box Office, Ground Floor
Name badges, abstract USBs, Final Programs and AOPMC meeting bags can be collected at the AOPMC Registration Area.

Registration Desk hours are as follows:
Friday, March 11: 8:00 – 18:00
Saturday, March 12: 7:00 – 18:00
Sunday, March 13: 7:00 – 16:00

Special Accessibility Needs
MDS will make every effort to work with the Marriott to accommodate these requests. Delegates requiring special arrangements in order to fully participate in the meeting should provide a written description of such needs to the registration desk upon arrival.
Marriott Grand Ballroom Floor Plan

**Ground Floor**

- Registration
- Exhibits and Coffee Breaks:
  - Executive Conference Rooms 7 and 9
  - Ceremonial Hall
- Posters

**Second Floor**

- Breakout Sessions
- Meal Symposia
- Plenary Sessions (Sunday)
- Plenary Sessions (Friday and Saturday)
- 11th APPA (Patient Meeting - Sunday)
- Speaker Ready Room

**Third Floor**

- Breakout Sessions

---

Marriott Grand Ballroom Floor Plan

**Ground Floor**

- Registration
- Exhibits and Coffee Breaks:
  - Executive Conference Rooms 7 and 9
  - Ceremonial Hall
- Posters

**Second Floor**

- Breakout Sessions
- Meal Symposia
- Plenary Sessions (Sunday)
- Plenary Sessions (Friday and Saturday)
- 11th APPA (Patient Meeting - Sunday)
- Speaker Ready Room

**Third Floor**

- Breakout Sessions
MDS-AOS Lectureship Awards

The MDS-AOS lectureships were established to honor Professors Yoshikuni Mizuno and Philip Thompson as experts in the field of Movement Disorders and to recognize their contributions as leaders within the International Parkinson and Movement Disorder Society. The lectureships also honor their leadership role in establishing the MDS Asian and Oceanian Section (MDS-AOS) in 2006 at the 10th International Congress of Parkinson’s Disease and Movement Disorders in Kyoto, Japan. The award lectures will be presented during the MDS-AOS Lectureship Plenary session on Sunday, March 13, 2016.

Session 3101: MDS-AOS Lectureship Awards
Sunday, March 13 8:00 – 9:30

2016 Philip Thompson Lectureship Award Recipient:
Lillian Lee, MD
4 Decades with XDP (Sex Linked Dystonia Parkinsonism)

The Philip Thompson Award Lecture is created to recognize an outstanding scholar and role-model clinician from the AOS region in the field of Movement Disorders. This year’s recipient is Dr. Lillian Lee.

Dr. Lillian V. Lee is head of the Philippine XDP Study Group based at the Philippine Children’s Medical Center in Quezon City, Philippines. The XDP Study Group tracks the clinical course of the disease called X-Linked Dystonia Parkinsonism (XDP, DYT3, Lubag), an adult onset, progressive, often debilitating movement disorder, manifesting predominantly with dystonia in combination with parkinsonism first reported in 1976 in 28 cases, occurring endemically among males in Panay Islands, Philippines. The group started surveillance of XDP cases since then.

Dr. Lee is also head of research and active consultant at the Child Neuroscience Center of the Philippine Children’s Medical Center. In July 2014, she received the appointment as Research Scientist in Neurology from Massachusetts General Hospital. She is a former Executive Director of the Philippine Children’s Medical Center, founding member of the Philippine Neurological Association, founding president and fellow of the Child Neurology Society of the Philippines and adviser to the Movement Disorder Society of the Philippines.

2016 Yoshikuni Mizuno Lecture Award Recipient:
Eng-King Tan, MD
Linking Lrrk2 with Parkinson’s Disease: From Bench to Bedside

The Yoshikuni Mizuno Award Lecture was created to recognize an outstanding scholar and inspiring neuroscientist from the AOS region in the field of Movement Disorders. This year’s recipient is Dr. Eng-King Tan.

Dr. Eng-King Tan is a senior consultant neurologist and clinician scientist at the National Neuroscience Institute (NNI) and a Professor at Duke-NUS graduate medical school. Dr. Tan completed his neurology training in Singapore and received further clinical fellowship training in Movement Disorders under the Ministry of Health Scholarship, and subsequently a research fellowship in Neurogenetics. He completed both fellowships at the Baylor College of Medicine, in Texas, USA.

Dr. Tan is an editor of the European Journal of Neurology, Parkinsonism Related Disorders, Parkinson’s disease Journal, and Basal Ganglia journal, and the chief editor of Annals Academy of Medicine, Singapore. Dr. Tan has served on various committees in the International Parkinson and Movement Disorder Society (MDS) and a founding member of the MDS Asian and Oceanian Section. He is also member of American Neurological Association. He has been involved in numerous educational activities in the Asian and Oceanian region.

Dr. Tan’s primary research interests are in clinical and functional genomics and experimental therapeutics in Parkinson’s disease and movement disorders.
Junior Award recipients are selected based on their significant contribution to the research in the field of Movement Disorders.

**Hiroyuki Todo, MD**  
*Japan*

**Attenuation of antecollis increases the blood concentration level of the levodopa in patients with the Parkinson’s disease and related disorders**  
*Hiroyuki Todo, Yuji Saitoh, Shoko Watanabe, Yohei Mukai, Takashi Sakamoto, Miho Murata (Kodaira, Japan)*

**Objective:** To investigate whether antecollis affects the pharmacokinetics of levodopa in patients with Parkinson’s disease (PD) and related disorders.

**Background:** Antecollis is one of the abnormal postures complicated with PD and related disorders. Antecollis can affect the levodopa pharmacokinetics by disturbing the drug delivery especially in the pharynx, delaying its absorption.

**Methods:** The subjects were 9 patients, including 4 PD patients, 3 multiple system atrophy (MSA) patients, 1 dementia with Lewy bodies (DLB) patient, and 1 progressive supranuclear palsy (PSP) patient, concomitant with antecollis. To investigate whether antecollis affects the pharmacokinetics of levodopa or the motor symptoms, we examined them before and until 240 minutes after oral administration of levodopa/decarboxylase inhibitor (L-dopa test). Then we did L-dopa test again after the treatment of antecollis by the physical therapy to show the effects of the improvement of antecollis.

**Results:** Before the treatment of antecollis, in 6 out of 9 patients (PD=2, MSA=2, DLB=1, PSP=1), levodopa kinetics showed two peaks. After the treatment of antecollis, the levodopa kinetics showed monophasic pattern in 5 patients, furthermore, the Cmax became higher than that before the treatment of antecollis in all of 9 patients. Interestingly, in a PD patient, the higher Cmax ameliorated the motor symptoms after the treatment of antecollis.

**Conclusions:** Our study indicates that antecollis affects the pharmacokinetics of levodopa. The treatment of antecollis could ameliorate the motor symptoms by getting the higher concentration of levodopa, especially in PD patients. Further studies are needed to elucidate the mechanisms of these pharmacokinetic changes of levodopa attributed to antecollis.
### Schedule-at-a-Glance

<table>
<thead>
<tr>
<th>Time</th>
<th>Friday, March 11</th>
<th>Saturday, March 12</th>
<th>Sunday, March 13</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00</td>
<td></td>
<td>Plenary Session I</td>
<td>Plenary Session III: MDS-AOS Lectureship Awards</td>
</tr>
<tr>
<td>8:30</td>
<td></td>
<td>Plenary Session III: MDS-AOS Lectureship Awards</td>
<td></td>
</tr>
<tr>
<td>9:00</td>
<td></td>
<td>Tea/Coffee Break</td>
<td>Plenary Session IV</td>
</tr>
<tr>
<td>9:30</td>
<td></td>
<td>Plenary Session II</td>
<td>Plenary Session IV</td>
</tr>
<tr>
<td>10:00</td>
<td></td>
<td>Poster Session/Late-Break</td>
<td>Plenary Session IV</td>
</tr>
<tr>
<td>10:30</td>
<td></td>
<td>Guided Poster Tours</td>
<td>Plenary Session IV</td>
</tr>
<tr>
<td>11:00</td>
<td></td>
<td>Break</td>
<td>Plenary Session IV</td>
</tr>
<tr>
<td>11:30</td>
<td></td>
<td>Break</td>
<td>Plenary Session IV</td>
</tr>
<tr>
<td>12:00</td>
<td>Ipsen Lunch Symposium</td>
<td>Lundbeck Lunch Symposium</td>
<td>Lunch Symposium</td>
</tr>
<tr>
<td>12:30</td>
<td>Break</td>
<td>Break</td>
<td>Break</td>
</tr>
<tr>
<td>13:00</td>
<td>Break</td>
<td>Break</td>
<td>Break</td>
</tr>
<tr>
<td>13:30</td>
<td>Novartis Symposium</td>
<td>Break</td>
<td>Break</td>
</tr>
<tr>
<td>14:00</td>
<td>Break</td>
<td>Break</td>
<td>Break</td>
</tr>
<tr>
<td>14:30</td>
<td>AOPMC Symposium</td>
<td>Parallel Sessions (3)</td>
<td>Parallel Sessions (3)</td>
</tr>
<tr>
<td>15:00</td>
<td></td>
<td>APPPA: Regional PD Societies Leadership Forum</td>
<td>Parallel Sessions (3)</td>
</tr>
<tr>
<td>15:30</td>
<td>Tea/Coffee Break</td>
<td>Tea/Coffee Break</td>
<td>(only for leaders of regional PD patient/caregiver Societies)</td>
</tr>
<tr>
<td>16:00</td>
<td>AbbVie Symposium</td>
<td>Break</td>
<td>Break</td>
</tr>
<tr>
<td>16:30</td>
<td></td>
<td>Break</td>
<td>Break</td>
</tr>
<tr>
<td>17:00</td>
<td>Break</td>
<td>Break</td>
<td>Break</td>
</tr>
<tr>
<td>17:30</td>
<td>UCB Symposium</td>
<td>Parallel Sessions (3)</td>
<td>Parallel Sessions (3)</td>
</tr>
<tr>
<td>18:00</td>
<td>Break</td>
<td>Break</td>
<td>Parallel Sessions (3)</td>
</tr>
<tr>
<td>18:30</td>
<td></td>
<td>Break</td>
<td>Parallel Sessions (3)</td>
</tr>
<tr>
<td>18:30</td>
<td></td>
<td>Break</td>
<td>Parallel Sessions (3)</td>
</tr>
<tr>
<td>19:00</td>
<td>Opening Ceremony</td>
<td>Video Tournament</td>
<td></td>
</tr>
<tr>
<td>19:30</td>
<td>Opening Reception</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:00</td>
<td>Medtronic Dinner Symposium</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Registration Desk Hours**
- **Friday, March 11:** 8:00 – 18:00
- **Saturday, March 12:** 7:00 – 18:00
- **Sunday, March 13:** 7:00 – 16:00

**Exhibition Hours**
- **Friday, March 11:** 13:00 – 20:00
- **Saturday, March 12:** 9:00 – 18:30
- **Sunday, March 13:** 9:00 – 16:30

**Exhibition Hours**
- **Friday, March 11:** 13:00 – 20:00
- **Saturday, March 12:** 9:00 – 18:30
- **Sunday, March 13:** 9:00 – 16:30

The 11th International Symposium of the Asian and Pacific Parkinsonism Association (APPA), a meeting for People Living with Parkinson’s and their caregivers 9:00 – 16:00
Friday, March 11, 2016

1101  Ipsen Lunch Symposium
     Role of Botulinum Toxin in the Management of Spasticity
     (Sponsored by Ipsen)
     12:00 – 13:00
     Location: Ballroom AB, Second Floor
     New Data for Abobotulinumtoxin A in the Treatment of Adults with Upper Limb Spasticity
     Jean-Michel Gracies
     France
     Results from an International Survey of Patients with Spasticity
     Raymond Rosales
     Philippines

1102  Novartis Symposium
     Challenges, Trends and Future Perspectives in Parkinson’s Disease and Dementia: A Novartis Symposium
     (Sponsored by Novartis)
     13:15-14:15
     Location: Ballroom CD, Second Floor
     Chair: Nobutaka Hattori
     Japan
     Effective Management of Motor Fluctuations in Advanced Parkinson’s Disease – Current and Future Prospectives
     Eng-King Tan
     Singapore
     Parkinson’s Disease Dementia: Where Memory Fails and Management Re-Challenged
     Raymond Rosales
     Philippines

1103  AOPMC Symposium
     Movement Disorders in Autoimmune Disease and Paraneoplastic Disorders
     14:30-15:30
     Location: Ballroom CD, Second Floor
     Chairs: Donna Buhat
     Philippines
     Vinay Goyal
     India
     Movement Disorders Associated with Autoimmune Diseases
     Simon Lewis
     Australia
     Paraneoplastic Movement Disorders
     Vinay Goyal
     India

At the conclusion of this session, participants should be better able to:
1. Identify the phenomena of movement disorders in autoimmune disease and paraneoplastic disorders
2. Recognize the underlying pathogenesis
3. Describe how to manage patients with these diseases
5th AOPMC Scientific Program

Friday, March 11, 2016, continued

1104 AbbVie Symposium
Advanced Parkinson’s Disease – Natural Progression, Emerging Data and Patient Profile Considerations in the Clinical Setting
(Sponsored by AbbVie)
16:00-17:00
Location: Ballroom CD, Second Floor
Chair: Carolyn Sue
Australia
Advanced Parkinson’s Disease Landscape – Incidence, Definition and Patient Considerations Including Emerging Data for Advanced Parkinson’s Disease Treatment Options
Thomas Kimber
Australia
Which Patient for Which Therapy and When? Is There a Clear Patient Profile for the Different Advanced Parkinson’s Disease Therapies?
Andrew Evans
Australia
Opening Ceremony
(Sponsored by Boehringer Ingelheim)
18:30 – 19:30
Location: Ballroom CD, Second Floor
Opening Reception
19:30 – 20:00
Location: Ballroom Foyer, Second Floor

1105 UCB Symposium
How Can We Empower Our Parkinson’s Disease Patients and Optimize Clinical Outcomes?
(Sponsored by UCB)
17:15 – 18:15
Location: Ballroom CD, Second Floor
Chair: Andrew Evans
Australia
Patients & Neurologists – A Partnership for Success
Andrew Evans
Australia
Integrating Patient Concerns into Disease Management
Shen-Yang Lim
Malaysia
Joint Decisions on Treating Nocturnal Symptoms – What Do Patients Need to Know?
Roongroj Bhidayasiri
Thailand

1106 Medtronic Dinner Symposium
Incorporating Medtronic DBS in Your Practice
(Sponsored by Medtronic)
20:00 – 21:00
Location: Ballroom AB, Second Floor
Chair: Roland Dominic Jamora
Philippines
When is the Right Time for DBS?
Shen-Yang Lim
Malaysia
Optimizing DBS Outcomes – A Review of Recent Evidence
Vincent Mok
People’s Republic of China
Saturday, March 12, 2016

2101 Plenary Session I

**Basal Ganglia Circuitry and Receptors: New Developments in Understanding Movement Disorders**

8:00 – 9:30

**Opening Keynote Address: Psychogenic Movement Disorders**
Oscar Gershanik
Argentina

8:30 **The Basal Ganglia Circuitry: Overview and New Developments**
Philip Thompson
Australia

8:50 **The Default Mode Networks in The Basal Ganglia Through Neuroimaging**
Shunsuke Kobayashi
Japan

9:10 **Moving New Developments of Basal Ganglia Circuitry into Clinical Translation**
Jawad Bajwa
Saudi Arabia

Recommended Audience: Basic scientists, Clinical academicians, Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Develop a clinical working framework in approaching psychogenic movement disorders
2. Integrate new developments in the understanding of the basal ganglia circuitry, as it relates to movement disorders
3. Recognize the relevance our current knowledge of the basal ganglia has to the clinical presentation of movement disorders
4. Describe the emerging role of different neural networks in translating a better understanding and treatment of movement disorders

2102 Plenary Session II

**Phenotype/Genotype in Movement Disorders**

10:00 – 11:30

**The Very Latest on the Genetics of Dystonia**
Christine Klein
Germany

10:30 **Keeping Up with New Genetic Predispositions and Mutations in Parkinson’s Disease**
Manabu Funayama
Japan

11:00 **Unique Genetic Considerations in Movement Disorders in the Asian Population**
Ruey-Meei Wu
Taiwan

Recommended Audience: Basic scientists, Clinical academicians, Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Update the very latest on dystonia genomics
2. Describe the genetic etiologies and underlying mechanisms causing parkinsonism
3. Assess the ethnic difference of genetic etiology in Parkinson’s disease and other movement disorders in the Asian population
5th AOPMC Scientific Program

Saturday, March 12, 2016, continued

2203 Lundbeck Lunch Symposium

Asian Perspectives on Recognition and Treatment of Levodopa - Induced Motor Complications in Parkinson’s Disease
(Sponsored by H. Lundbeck A/S)
13:00 – 14:00
Location: Ballroom AB, Second Floor
Chair: Roland Dominic Jamora
Philippines

Focus on Parkinson’s Disease in the Philippines
Roland Dominic Jamora
Philippines

Clinical Management of Parkinson’s Disease in Asia – Recent Developments in use of Levodopa
Piu Bill Chan
People’s Republic of China

Levodopa - Related Motor Complications in Parkinson’s Disease -Mechanisms and Treatment Approaches
Werner Poewe
Austria

2304 Parallel Session

How to Engage in Clinical Trials for Movement Disorders
14:30 – 16:00
Location: VIP West, Third Floor
Chairs: Hubert Fernandez
USA/Philippines
Masahiro Nomoto
Japan

Introduction to Clinical Trials: The Basics and the Winning Formula
Hubert Fernandez
USA/Philippines

What You Need To Know Before Conducting Clinical Trials - Ethics, Regulatory Concerns, and Investigator Responsibilities
Janis Miyasaki
Canada

Avoiding/Surviving the Dreaded ‘Audit’: How Regulators Spot Trouble
Anne Constantino
USA

Maximize Recruitment and Retention While Minimizing Placebo Effect: An Interactive Session with the Audience
The Panel

Recommended Audience: Clinical academicians, Health Professionals (Non-physician), Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Provide an overview of the different phases of clinical trials and the required set up in conducting clinical trial
2. Recognize the ethical, clinical and regulatory responsibilities of a clinical trial investigator
3. Recognize various techniques to maximize recruitment and retention and minimize placebo effect in clinical trials
### 2305 Parallel Session

**Management of Common and Intractable Cervical Dystonia**  
14:30 – 16:00  
**Location:** Executive Room 11 and 12, Second Floor  
**Chairs:** Ying-Zu Huang, Taiwan  
Hee-Tae Kim, Korea  

14:30 **Common and Uncommon Clinical Presentations and Etiologies of Cervical Dystonia**  
Erle Lim, Singapore  

15:00 **Non-Surgical Managements for Cervical Dystonia**  
Barry Snow, New Zealand  

15:30 **Surgical Interventions to Consider for Cervical Dystonia: When And What**  
Takaomi Taira, Japan  

**Recommended Audience:** Clinical academicians, Practitioners, Students/Residents/Trainees  
At the conclusion of this session, participants should be better able to:  
1. Recognize the clinical presentations and etiologies of cervical dystonia and review the treatment options of intractable cervical dystonia  
2. Assess the current evidence base of applying novel intervention (tDCS and cerebellar stimulation) for intractable cervical dystonia  
3. Recognize the role of surgical interventions for the treatment of cervical dystonia

### 2306 Parallel Session

**Hyperkinetic Movement Disorders: The Common, The Rare, and The Traps**  
14:30 – 16:00  
**Location:** Ballroom CD, Second Floor  
**Chairs:** Madhuri Behari, India  
Frandy Susatia, Indonesia  

14:30 **What You Cannot Afford to Miss: Common Hyperkinetic Movement Disorders**  
Werner Poewe, Austria  

15:00 **How To Be The Hero: Recognizing Uncommon Hyperkinetic Movement Disorders**  
Thien Thien Lim, Malaysia  

15:30 **Is It Real Or Not? Spotting Mimickers of Hyperkinetic Movement Disorders**  
Mohit Bhatt, India  

**Recommended Audience:** Clinical academicians, Practitioners, Students/Residents/Trainees  
At the conclusion of this session, participants should be better able to:  
1. Recognize the phenotypic spectrum of common hyperkinetic movement disorders  
2. Describe the phenotypic spectrum of uncommon hyperkinetic movement disorders  
3. Recognize mimics of hyperkinetic movement disorders
## 5th AOPMC Scientific Program

### Saturday, March 12, 2016, continued

<table>
<thead>
<tr>
<th>Session</th>
<th>Parallel Session</th>
<th>Location</th>
<th>Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>2407</strong></td>
<td>Spasticity, Plasticity and Botulinum Toxin Therapy - The Word Gets Around</td>
<td>Executive Room 11 and 12, Second Floor</td>
<td>Cid Diesta (Philippines), Yasuyuki Okuma (Japan)</td>
</tr>
<tr>
<td><strong>16:30</strong></td>
<td>The Pathophysiology of Spasticity: Integrating the Old and New Concepts</td>
<td></td>
<td>Jean-Michel Gracies (France)</td>
</tr>
<tr>
<td><strong>17:00</strong></td>
<td>Brain Plasticity in Spasticity with Toxin Therapy? Evidence from Imaging Studies</td>
<td></td>
<td>Petr Kanovsky (Czech Republic)</td>
</tr>
<tr>
<td><strong>17:30</strong></td>
<td>Optimizing Spasticity Management with Botulinum Toxin A Therapy</td>
<td></td>
<td>Raymond Rosales (Philippines)</td>
</tr>
</tbody>
</table>

**Recommended Audience:** Clinical academicians, Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Integrate old and new concepts in understanding the pathophysiology of spasticity
2. Summarize the therapeutic roles of Botulinum toxin A injections in spasticity management
3. Define brain plasticity in spasticity in the context of Botulinum toxin A therapy, focusing on the evidence from MRI studies

<table>
<thead>
<tr>
<th>Session</th>
<th>Parallel Session</th>
<th>Location</th>
<th>Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>2408</strong></td>
<td>Appreciating Hyperkinetic Movements Based on Their Patho-Mechanism</td>
<td>VIP West, Third Floor</td>
<td>Yoshikuni Mizuno (Japan), Miho Murata (Japan)</td>
</tr>
<tr>
<td><strong>16:30</strong></td>
<td>How Can Understanding the Pathomechanism of Tremors and Ataxia Alter Our Diagnosis and Treatment?</td>
<td></td>
<td>Victor Fung (Australia)</td>
</tr>
<tr>
<td><strong>17:00</strong></td>
<td>Overview of the Patho-Mechanisms Underlying Voluntary and Involuntary Movements</td>
<td></td>
<td>Yoshikazu Ugawa (Japan)</td>
</tr>
<tr>
<td><strong>17:30</strong></td>
<td>Recognizing Dystonic Types and Optimizing Treatment Through the Mechanistic Lens</td>
<td></td>
<td>Ryuji Kaji (Japan)</td>
</tr>
</tbody>
</table>

**Recommended Audience:** Clinical academicians, Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Describe mechanisms underlying four groups of hyperkinetic involuntary movements: Myoclonus, tremor, chorea-ballism, dystonia-athetosis groups
2. Differentiate tremors and ataxia and their treatment options based on their mechanism
3. Recognize dystonic forms and select optimal treatments using drugs, botulinum toxin and DBS through the pathomechanistic standpoint
Saturday, March 12, 2016, continued

<table>
<thead>
<tr>
<th>2409</th>
<th>Parallel Session</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hot Topics in Parkinson's Disease Non-Motor Symptoms</strong></td>
<td>16:30 – 18:00</td>
</tr>
<tr>
<td>Location: Ballroom CD, Second Floor</td>
<td></td>
</tr>
</tbody>
</table>
| Chairs: Norlinah Ibrahim 
*Malaysia* 
Anthony Piano 
*Philippines* | 
| **16:30** Gastrointestinal Dysfunction in Parkinson’s Disease: Etio-Pathogenetic Aspects | 
Shen-Yang Lim 
*Malaysia* | 
| **17:00** The Painful Truth About Pain in Parkinson’s Disease | 
Beom Jeon 
*Korea* | 
| **17:30** Autonomic Manifestations in Parkinson’s Disease | 
Ryuji Sakakibara 
*Japan* | 

Recommended Audience: Clinical academicians, Health Professionals (Non-physician), Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Explain the role of the gut in the pathogenesis of Parkinson’s disease (disease causation, and/or worsening of disease severity)
2. Elucidate the occurrence of pain and its pathogenesis in Parkinson’s disease
3. Describe the role of the autonomic nervous system in the pathogenesis of Parkinson’s disease (disease causation, and/or worsening of disease severity)

MDS-AOS Video Tournament
18:30 – 20:30
Location: Ballroom CD, Second Floor
### 5th AOPMC Scientific Program

#### Sunday, March 13, 2016

<table>
<thead>
<tr>
<th>3101</th>
<th>Plenary Session III</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MDS-AOS Lectureship Awards</strong>&lt;br&gt;8:30 – 9:30</td>
<td><strong>Location:</strong> Ballroom AB, Second Floor&lt;br&gt;<strong>Chairs:</strong> Nobutaka Hattori&lt;br&gt;Japan&lt;br&gt;Raymond Rosales&lt;br&gt;Philippines</td>
</tr>
<tr>
<td><strong>Philip Thompson Lecture:</strong> Four Decades with XDP (Sex Linked Dystonia Parkinsonism)&lt;br&gt;8:00</td>
<td><strong>Lillian Lee&lt;br&gt;Philippines</strong></td>
</tr>
<tr>
<td><strong>Yoshikuni Mizuno Lecture:</strong> Linking Lrrk2 with Parkinson’s Disease: From Bench to Bedside&lt;br&gt;8:30</td>
<td><strong>Eng-King Tan&lt;br&gt;Singapore</strong></td>
</tr>
<tr>
<td><strong>Junior Award Lectureships</strong>&lt;br&gt;9:00</td>
<td><strong>Hiroyuki Todo&lt;br&gt;Japan</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>3102</th>
<th>Plenary Session IV</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Care in Parkinson’s Disease</strong>&lt;br&gt;10:00 – 11:30</td>
<td><strong>Location:</strong> Ballroom AB, Second Floor&lt;br&gt;<strong>Chairs:</strong> Vinay Goyal&lt;br&gt;India&lt;br&gt;Mitsutoshi Yamamoto&lt;br&gt;Japan</td>
</tr>
<tr>
<td><strong>Gaps in the Diagnosis and Care of Parkinson’s Disease: Focus on Asia</strong>&lt;br&gt;10:00</td>
<td><strong>Roland Dominic Jamora&lt;br&gt;Philippines</strong></td>
</tr>
<tr>
<td><strong>The Critical Role of Neurorehabilitation in Parkinson’s Disease Care</strong>&lt;br&gt;10:30</td>
<td><strong>Jorge Hernandez Franco&lt;br&gt;Mexico</strong></td>
</tr>
<tr>
<td><strong>Why Palliative Care in Parkinson’s Disease Should Be Everyone’s Responsibility</strong>&lt;br&gt;11:00</td>
<td><strong>Janis Miyasaki&lt;br&gt;Canada</strong></td>
</tr>
</tbody>
</table>

**Recommended Audience:** Clinical academicians, Health Professionals (Non-physician), Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Identify key problem areas in the diagnosis and care of Parkinson’s disease in Asia
2. Define the role of neurorehabilitation in the management of Parkinson’s disease
3. Integrate the principles of palliative care and its applicability in Parkinson’s disease management

<table>
<thead>
<tr>
<th>3103</th>
<th>Lunch Symposium</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>The Old Versus the New UPDRS</strong>&lt;br&gt;13:00 – 14:00</td>
<td><strong>Location:</strong> Ballroom AB, Second Floor&lt;br&gt;<strong>Hubert Fernandez&lt;br&gt;USA/Philippines</strong></td>
</tr>
</tbody>
</table>
### 5th AOPMC Scientific Program

#### Sunday, March 13, 2016, continued

<table>
<thead>
<tr>
<th>3304</th>
<th>Parallel Session</th>
<th>3305</th>
<th>Parallel Session</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Neurobehavioral Impairment in Parkinson’s Disease</strong>&lt;br&gt;14:30 – 16:00</td>
<td><strong>Manifesting Movement Disorders in Neuromuscular Disease</strong>&lt;br&gt;14:30 – 16:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Location: Ballroom AB, Second Floor</td>
<td>Location: Executive Room 11 and 12, Second Floor</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chairs: Jae Woo Kim&lt;br&gt;Korea&lt;br&gt;Hui Fang Shang&lt;br&gt;People’s Republic of China</td>
<td>Chairs: Ritsuko Hanajima&lt;br&gt;Japan&lt;br&gt;Arlene Ng&lt;br&gt;Philippines</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Drugs, Sex and Gambling: How to Approach Impulse Control Disorders in Parkinson’s Disease</strong>&lt;br&gt;K. Ray Chaudhuri&lt;br&gt;United Kingdom</td>
<td><strong>Peripheral Mechanisms of Movement Disorders</strong>&lt;br&gt;Con Yiannikas&lt;br&gt;Australia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td>14:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Psychosis in Parkinson’s Disease: Is it a Serious Problem or is it Over-Rated?</strong>&lt;br&gt;Hubert Fernandez&lt;br&gt;USA/Philippines</td>
<td><strong>Movement Disorders Due to Nerve Hyper Excitability</strong>&lt;br&gt;Kimiyoshi Arimura&lt;br&gt;Japan</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td>15:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>The Latest Developments in Cognitive Impairment in Parkinson’s Disease</strong>&lt;br&gt;Andrew Evans&lt;br&gt;Australia</td>
<td><strong>Movement Disorders in Mitochondrial Disease</strong>&lt;br&gt;Carolyn Sue&lt;br&gt;Australia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td>15:30</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Recommended Audience: Basic scientists, Clinical academicians, Health Professionals (Non-physician), Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Recognize how to screen, detect, evaluate and treat impulse control disorders in Parkinson’s disease
2. Recognize and treat psychosis in Parkinson’s disease
3. Recognize new developments in the recognition and treatment of cognitive impairment in Parkinson’s disease

---

**3305** **Parallel Session**

<table>
<thead>
<tr>
<th>3305</th>
<th>Parallel Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manifesting Movement Disorders in Neuromuscular Disease&lt;br&gt;14:30 – 16:00</td>
<td><strong>Peripheral Mechanisms of Movement Disorders</strong>&lt;br&gt;Con Yiannikas&lt;br&gt;Australia</td>
</tr>
<tr>
<td>Location: Executive Room 11 and 12, Second Floor</td>
<td><strong>Movement Disorders Due to Nerve Hyper Excitability</strong>&lt;br&gt;Kimiyoshi Arimura&lt;br&gt;Japan</td>
</tr>
<tr>
<td><strong>Movement Disorders in Mitochondrial Disease</strong>&lt;br&gt;Carolyn Sue&lt;br&gt;Australia</td>
<td><strong>Movement Disorders Due to Nerve Hyper Excitability</strong>&lt;br&gt;Kimiyoshi Arimura&lt;br&gt;Japan</td>
</tr>
<tr>
<td>15:00</td>
<td>15:30</td>
</tr>
</tbody>
</table>

Recommended Audience: Clinical academicians, Health Professionals (Non-physician), Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Utilize an efficient bedside examination in the evaluation of muscle cramps and spasms
2. Identify neuropathic and myopathic causes of movement disorders
3. Recognize movements arising from mitochondrial diseases
## 5th AOPMC Scientific Program

### Sunday, March 13, 2016, continued

<table>
<thead>
<tr>
<th>Session</th>
<th>Parallel Session</th>
<th>Time</th>
<th>Location</th>
<th>Chairs</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>3306</td>
<td><strong>Atypical Parkinsonism</strong></td>
<td>14:30 – 16:00</td>
<td>VIP West, Third Floor</td>
<td>Leonardo Fugoso</td>
<td>USA</td>
</tr>
<tr>
<td></td>
<td><strong>Ryo Hasegawa</strong></td>
<td></td>
<td></td>
<td>Ryo Hasegawa</td>
<td>Japan</td>
</tr>
<tr>
<td></td>
<td><strong>When it is NOT Parkinson’s Disease:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Clinical Spectrum of Atypical Parkinsonisms</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Louis Tan</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Singapore</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td><strong>The Role of Imaging and Other Modalities in Atypical Parkinsonism</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Roongroj Bhidayasiri</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Thailand</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td><strong>Management of Atypical Parkinsonism</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Mandy Au-Yeung</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Hong Kong</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Recommended Audience:** Clinical academicians, Health Professionals (Non-physician), Practitioners, Students/Residents/Trainees

**At the conclusion of this session, participants should be better able to:**

1. Recognize and describe the clinical presentations of various atypical parkinsonian syndromes
2. Integrate the emerging role of imaging modalities in the diagnosis of atypical parkinsonian syndromes
3. Identify the treatment options of the most common atypical parkinsonian disorders

<table>
<thead>
<tr>
<th>Session</th>
<th>Parallel Session</th>
<th>Time</th>
<th>Location</th>
<th>Chairs</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>3407</td>
<td><strong>Neuromodulation in Parkinson’s Disease and Other Movement Disorders: The Good, the Bad and the Ugly</strong></td>
<td>16:30 – 18:00</td>
<td>Executive Room 11 and 12, Second Floor</td>
<td>Praween Lolekha</td>
<td>Thailand</td>
</tr>
<tr>
<td></td>
<td><strong>Yasushi Shimo</strong></td>
<td></td>
<td></td>
<td></td>
<td>Japan</td>
</tr>
<tr>
<td>16:30</td>
<td><strong>Neuromodulation in Parkinson’s Disease: How Does it Really Work?</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Simon Lewis</strong></td>
<td></td>
<td></td>
<td></td>
<td>Australia</td>
</tr>
<tr>
<td>17:00</td>
<td><strong>Perils and Pitfalls of Neuromodulation in Parkinson’s Disease</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Genko Oyama</strong></td>
<td></td>
<td></td>
<td></td>
<td>Japan</td>
</tr>
<tr>
<td>17:30</td>
<td><strong>The Expanding Role of Neuromodulation in Other Movement Disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Sun Ha Paek</strong></td>
<td></td>
<td></td>
<td></td>
<td>Korea</td>
</tr>
</tbody>
</table>

**Recommended Audience:** Clinical academicians, Health Professionals (Non-physician), Practitioners, Students/Residents/Trainees

**At the conclusion of this session, participants should be better able to:**

1. Describe the physiological basis of neuromodulation
2. Assess the benefits, possible side effects and long term outcome of neuromodulation
3. Identify other movement disorders that may benefit from neuromodulation
Sunday, March 13, 2016, continued

3408 Parallel Session

**Sleep Disturbances in Parkinson’s Disease and Other Movement Disorders**
16:30 – 18:00

Location: VIP West, Third Floor

Chairs: Maria Victoria Alvarez
USA
Win Min Thit
Myanmar

**16:30**

*Idiopathic IRBD (Idiopathic REM Sleep Behavioral Disorder) and Parkinson’s Disease*
Jee-Young Lee
Korea

**17:00**

*Medical Management of Sleep Disturbances in Parkinson’s Disease*
Tim Anderson
New Zealand

**17:30**

*Addressing the Most Common Movement Disorder: Update on Restless Leg Syndrome*
Thomas Kimber
Australia

Recommended Audience: Clinical academicians, Health Professionals (Non-physician), Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Define the characteristics of IRBD and Parkinson’s disease
2. Identify the treatment options of the most common sleep disorders in Parkinson’s disease and other movement disorders
3. Integrate the latest developments in the understanding and treatment of restless legs syndrome

3409 Parallel Session

**Subclinical Parkinson’s Disease: Past, Present and Future**
16:30 – 18:00

Location: Ballroom AB, Second Floor

Chairs: Shengdi Chen
People’s Republic of China
Taku Hatano
Japan

**16:30**

*Biomarkers of Neurodegeneration*
Baorong Zhang
People’s Republic of China

**17:00**

*Pathophysiologic Basis of Neurodegeneration*
Piu Bill Chan
People’s Republic of China

**17:30**

*Parkinson’s at Risk Syndrome (PARS) and Prodromes*
Yih-Ru Wu
Taiwan

Recommended Audience: Clinical academicians, Health Professionals (Non-physician), Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Recognize how biomarkers help in our understanding of neurodegenerative diseases
2. Integrate our understanding of neurodegeneration from the pathophysiologic standpoint
3. Identify the range of clinical markers of early/prodromal Parkinson’s disease
Faculty List

Alvarez, Maria Victoria, USA ........................................... 3408
Anderson, Tim, New Zealand ........................................... 3408
Arimura, Kimiyoshi, Japan ........................................... 3305
Au-Yeung, Mandy, Hong Kong ........................................... 3306
Bajwa, Jawad A., Saudi Arabia ........................................ 2101
Behari, Madhuri, India ........................................... 2306
Bhatt, Mohit, India .................................................. 2306
Bhidayasiri, Roongroj, Thailand ..................................... 1105, 3306
Bohlega, Saeed, Saudi Arabia ........................................ 2101
Buhat, Donna, Philippines ........................................... 1103
Chan, Piu Bill, People’s Republic of China ......................... 2203, 3409
Chaudhuri, K. Ray, United Kingdom .................................. 3304
Chen, Jou-Hsien, Taiwan ........................................... 2101
Chen, Shengdi, People’s Republic of China ......................... 3409
Constantino, Anne, USA ........................................... 2304
Diesta, Cid, Philippines ........................................... 2407
Evans, Andrew, Australia ........................................... 1104, 1105, 3304
Fernandez, Hubert, USA/Philippines ................................. 2304, 3304
Fugoso, Jr., Leonardo, USA ........................................... 3306
Funayama, Manabu, Japan ........................................... 2102
Fung, Victor, Australia ........................................... 2408
Gershanik, Oscar, Argentina ........................................... 2101
Goyal, Vinay, India .................................................. 1103, 3102
Gracies, Jean-Michel, France ........................................ 1101, 2407
Hanajima, Ritsuko, Japan ........................................... 3305
Hatano, Taku, Japan .................................................. 3409
Hattori, Nobutaka, Japan ........................................... 1102, 2102, 3101
Hernandez Franco, Jorge, Mexico ...................................... 3102
Huang, Ying-Zu, Taiwan ........................................... 2305
Ibrahim, Norlinah, Malaysia ........................................... 2409
Jamora, Roland Dominic, Philippines ............................... 1106, 2203, 3102
Jeon, Beom, Korea .................................................. 2409
Kaji, Ryuji, Japan .................................................. 2408
Kanovsky, Petr, Czech Republic ........................................ 2407
Kim, Hee-Tae, Korea .................................................. 2305
Kim, Jae Woo, Korea .................................................. 3304
Kimber, Thomas, Australia ........................................... 1104, 3408
Klein, Christine, Germany ........................................... 2102
Kobayashi, Shunsuke, Japan ........................................... 2101
Lee, Jee-Young, Korea ........................................... 3408
Lee, Lillian, Philippines ........................................... 3101
Lewis, Simon, Australia ........................................... 1103, 3407
Lim, Erle Chuen-Hian, Singapore ..................................... 2305
Lim, Shen-Yang, Malaysia ........................................... 1105, 1106, 2409
Lim, Thien Thien, Malaysia ........................................... 2306
Lolekha, Praween, Thailand ........................................... 3407
Miyasaki, Janis, Canada ........................................... 2304, 3102
Mizuno, Yoshikuni, Japan ........................................... 2408
Mok, Vincent, People’s Republic of China ......................... 1106
Murata, Miho, Japan .................................................. 2408
Ng, Arlene, Philippines ........................................... 3305
Nomoto, Masahiro, Japan ........................................... 2304
Okuma, Yasuyuki, Japan ........................................... 2407
Oyama, Genko, Japan ........................................... 3407
Paek, Sun Ha, Korea ........................................... 3407
Piano, Anthony, Philippines ........................................... 2409
Poewe, Werner, Austria ........................................... 2203, 2306
Rosales, Raymond, Philippines ........................................ 1101, 1102, 2407, 3101
Sakakibara, Ryuji, Japan ........................................... 2409
Shang, Hui Fang, People’s Republic of China ...................... 3304
Shimo, Yasushi, Japan ........................................... 3407
Snow, Barry, New Zealand ........................................... 2305
Sue, Carolyn, Australia ........................................... 1104, 3305
Susatia, Frandy, Indonesia ........................................... 2306
Taira, Takaomi, Japan ........................................... 2305
Takahashi, Ryosuke, Japan ........................................... 3306
Tan, Eng-King, Singapore ........................................... 1102, 2102, 3101
Tan, Louis, Singapore ........................................... 3306
Thit, Win Min, Myanmar ........................................... 3408
Thompson, Philip, Australia ........................................... 2101
Ugawa, Yoshikazu, Japan ........................................... 2408
Wu, Ruey-Meei, Taiwan ........................................... 2102
Wu, Yih-Ru, Taiwan ........................................... 3409
Yamamoto, Mitsutoshi, Japan ........................................... 3102
Yiannikas, Con, Australia ........................................... 3305
Zhang, Baorong, People’s Republic of China ...................... 3409
### Saturday, March 12, 2016
Poster Session: 11:30 – 12:30
Poster Viewing: 8:00 – 18:00
Location: Marriott Grand Ballroom, Ground Floor Foyer

- Huntington's disease ............................................................... 1-5
- Parkinsonism (secondary and parkinsonism-plus) .................. 6-26
- Parkinson's disease: Clinical Trials ................................. 27-42
- Parkinson's disease: Electrophysiology ......................... 43-47
- Parkinson's disease: Neuropharmacology ....................... 48-57
- Parkinson's disease: Neurorehabilitation ....................... 58-65
- Parkinson's disease: Non-motor phenotypes ................. 66-94
- Parkinson's disease: Phenomenology ......................... 95-97
- Parkinson's disease: Quality of Life/Caregiver burden .... 98-106
- Parkinson's disease: Rating scales ............................. 107-111
- Surgical Therapy: Parkinson's disease ..................... 112-116

### Sunday March 13, 2016
Poster Session: 11:30 – 12:30
Poster Viewing: 8:00 – 18:00
Location: Marriott Grand Ballroom, Ground Floor Foyer

- Ataxia ........................................................................ 117-120
- Basic Science ................................................................. 121-153
- Chorea (non-Huntington’s disease) ............................... 154-155
- Drug-Induced Movement Disorders .......................... 156-158
- Dystonia ........................................................................ 159-168
- Epidemiology ................................................................. 169-177
- Genetics ........................................................................ 178-187
- Lewy Body Dementia and other dementias in movement disorders ................................. 188
- Myoclonus .................................................................... 189-191
- Neuroimaging ............................................................... 192-201
- Neuropharmacology .................................................... 202-207
- Neurorehabilitation in Dystonia ................................. 208
- Other movement disorders ....................................... 209-213
- Pediatric Movement disorder .................................. 214-216
- Quality of life/caregiver burden in movement disorders . 217
- Restless legs syndrome ............................................... 218-220
- Spasticity ....................................................................... 221-223
- Surgical Therapy: Other Movement Disorders .......... 224-225
- Tremor .......................................................................... 226-230
- Wilson’s disease, storage and metabolic movement disorders ........................................... 231-233

*A listing of the abstracts by topic is found on pages 33-43.
Guided Poster Tours

Guided Poster Tours will take place during the regular poster sessions on March 12 – 13, 2016. They will be led by members of the AOPMC faculty and the authors will be present to discuss the abstracts. There will be ten total Guided Poster Tours with five simultaneous tours per day on Saturday, March 12 and Sunday, March 13. Anyone is welcome to attend; please meet at the first poster of the tour at the start time. Each tour will highlight exceptional posters.

The MDS-AOS would like to acknowledge Aguettant for their support of the Guided Poster Tours through an unrestricted grant.

Saturday, March 12, 2016

11:30 – 12:30
Location: Marriott Grand Ballroom, Ground Floor Foyer
Guided Poster Tour 1: Parkinson’s Disease: Rating Scales
Parkinson’s Disease: Clinical Trials
Parkinson’s Disease: Surgery
Tour Leader: Hubert Fernandez

Posters featured in this tour:

<table>
<thead>
<tr>
<th>Poster #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>27</td>
<td>Immune response mediators as a factor of Parkinson’s disease</td>
</tr>
<tr>
<td>35</td>
<td>Determining the driving ability of Parkinson’s disease patients and controls by using a computer-based 3D driving simulator.</td>
</tr>
<tr>
<td>38</td>
<td>123-I-Ioflupane SPECT in combination with MIBG myocardial scintigraphy in Parkinson’s disease: A case study.</td>
</tr>
<tr>
<td>39</td>
<td>The overview of the Japan Parkinson’s Progression Markers Initiative (J-PPMI)</td>
</tr>
<tr>
<td>40</td>
<td>The relationship among 123I-FP-CIT scintigraphy, 123I-MIBG cardiac scintigraphy, and olfactory function tests in Parkinson’s disease</td>
</tr>
<tr>
<td>107</td>
<td>Parkinson’s disease risk score (PDRS) for Parkinson’s disease screening in aging population: Effect of yoga and meditation</td>
</tr>
<tr>
<td>110</td>
<td>A novel patient diary for assessment of motor fluctuations and drug efficacy in Parkinson’s disease</td>
</tr>
<tr>
<td>115</td>
<td>Impulse control disorders in Parkinson’s disease - Impact of deep brain stimulation and other factors</td>
</tr>
</tbody>
</table>

Guided Poster Tour 2: Parkinson’s Disease: Quality of Life/Caregiver Burden
Parkinson’s Disease: Neurorehabilitation

Tour Leader: Anthony Piano

Posters featured in this tour:

<table>
<thead>
<tr>
<th>Poster #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>58</td>
<td>Risk and adverse outcomes of fractures in patients with Parkinson’s disease: two nationwide studies</td>
</tr>
<tr>
<td>60</td>
<td>The effect of the pilates method on the motor symptoms, depression and quality of life of Filipino patients</td>
</tr>
<tr>
<td>61</td>
<td>The relationship between body composition and postural instability in people with idiopathic Parkinson’s disease</td>
</tr>
<tr>
<td>63</td>
<td>Effect of Gait and Balance training on Parkinson’s Disease Patients after Bilateral STN-DBS</td>
</tr>
<tr>
<td>101</td>
<td>Levodopa-Carbidopa Intestinal Gel: The naso-jejunal phase, a redundant convention?</td>
</tr>
<tr>
<td>102</td>
<td>Influence of tremor on quality of life of patients with Parkinson disease</td>
</tr>
<tr>
<td>103</td>
<td>Increased risk of depression in patients with Parkinson’s disease: A nationwide cohort study</td>
</tr>
<tr>
<td>104</td>
<td>Fall and near fall risks in ambulatory Filipino patients with Parkinson’s disease</td>
</tr>
<tr>
<td>106</td>
<td>Non-motor features among motor subtypes in newly diagnosed Parkinson’s disease patients: a cohort study from Southwest China</td>
</tr>
</tbody>
</table>
## Guided Poster Tours

### Saturday, March 12, 2016, continued

#### Guided Poster Tour 3: Parkinson’s Disease: Neuropharmacology

**Tour Leader:** Raymond Rosales  
Posters featured in this tour:

<table>
<thead>
<tr>
<th>Poster #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>48</td>
<td>The role of orexin in Parkinson’s disease: A review of article</td>
</tr>
<tr>
<td>50</td>
<td>Dopaminergic therapy: on a number of complications as increasing of libido in patients with Parkinson’s disease and Parkinson’s syndrome</td>
</tr>
<tr>
<td>51</td>
<td>Combined levodopa carbidopa with Entacapone improves the motor complications in advanced parkinson disease</td>
</tr>
<tr>
<td>52</td>
<td>Neuroprotective effect of apocyanin, a NADPH oxidase inhibitor in lipopolysaccharide induced Parkinson’s disease model</td>
</tr>
<tr>
<td>55</td>
<td>Novel HDAC1/2 isoform-specific inhibitor K560 ameliorates MPP+/MPTP-mediated experimental Parkinson’s disease</td>
</tr>
<tr>
<td>56</td>
<td>Efficacy and tolerability of levetiracetam in the management of levodopa-induced dyskinesia in Parkinson’s disease: A meta-analysis</td>
</tr>
<tr>
<td>57</td>
<td>The efficacy and safety of Zonisamide as adjunctive therapy in Parkinson’s disease: a meta-analysis</td>
</tr>
</tbody>
</table>

#### Guided Poster Tour 4: Parkinson’s Disease: Non-Motor Phenotypes

**Tour Leader:** Mandy Au-Yeung  
Posters featured in this tour:

<table>
<thead>
<tr>
<th>Poster #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>69</td>
<td>Non-motor symptoms in Parkinson’s patients: The PALS (Early Parkinson’s Disease Longitudinal Singapore) study</td>
</tr>
<tr>
<td>71</td>
<td>Orthostatic hypotension and cardiac sympathetic denervation in Parkinson’s disease patients with REM sleep behavioral disorder</td>
</tr>
<tr>
<td>75</td>
<td>Lateral Geniculate Atrophy in Parkinson’s with Visual Hallucination</td>
</tr>
<tr>
<td>76</td>
<td>Apathy and striatal dopamine defects in non-demented patients with Parkinson’s disease</td>
</tr>
<tr>
<td>79</td>
<td>Intestinal dysbiosis and lowered serum lipopolysaccharide-binding protein in Parkinson’s disease</td>
</tr>
<tr>
<td>81</td>
<td>Assessment of motor imaginary of gait by Timed Up&amp;Go test and cognitive impairment in Parkinson’s disease</td>
</tr>
<tr>
<td>86</td>
<td>Progression of non-motor symptoms in Parkinson’s disease among different age populations: A two year follow-up study</td>
</tr>
<tr>
<td>87</td>
<td>Retinal nerve fiber layer thinning: A window into rapid eye movement sleep behavior disorders in Parkinson’s disease</td>
</tr>
<tr>
<td>93</td>
<td>A gene for risk taking: Effect of genotypic variants on decision making and impulsivity in Parkinson’s disease</td>
</tr>
</tbody>
</table>

#### Guided Poster Tour 5: Parkinsonism

**Tour Leader:** Jawad A. Bajwa  
Posters featured in this tour:

<table>
<thead>
<tr>
<th>Poster #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>7</td>
<td>Parkinsonian signs in patients with Alzheimer’s disease is not correlated with white matter hyperintensity: a Korean study</td>
</tr>
<tr>
<td>10</td>
<td>Coronary artery disease in patients with Parkinsonism syndrome with/without type 2 diabetes</td>
</tr>
<tr>
<td>16</td>
<td>Levodopa responsive secondary Parkinsonism in the setting of posterio reversible encephalopathy syndrome in the postpartum period</td>
</tr>
<tr>
<td>18</td>
<td>Comparison of cognitive symptoms in Parkinson’s disease and Parkinson plus syndrome</td>
</tr>
<tr>
<td>23</td>
<td>Clinical and polysomnographic features correlates to sleep-disordered breathing in Multiple System Atrophy</td>
</tr>
<tr>
<td>24</td>
<td>The pathological impact of oligodendrocyte lineage cells on multiple system atrophy</td>
</tr>
<tr>
<td>25</td>
<td>Proteomic and Interleukin-6 (IL6), estrogen receptor beta (ESR2) gene mutation analysis in Parkinson’s disease (PD)</td>
</tr>
</tbody>
</table>
Guided Poster Tours

Sunday, March 13, 2016
11:30 – 12:30
Location: Marriott Grand Ballroom, Ground Floor Foyer

Guided Poster Tour 6: Basic Science
Tour Leader: Carolyn Sue

Posters featured in this tour:

<table>
<thead>
<tr>
<th>Poster #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>122</td>
<td>Generation of naivertropic Induced pluripotent stem cells from Parkinson’s disease patients for high efficiency genetic manipulation</td>
</tr>
<tr>
<td>124</td>
<td>Alternative mitophagy suppresses the development of Parkin-related Parkinson’s disease</td>
</tr>
<tr>
<td>125</td>
<td>Forebrain-specific knockout of ESCRT-0/Hrs disrupts protein quality control and facilitates ER stress-mediated neurodegeneration via apoptotic and necroptotic pathways</td>
</tr>
<tr>
<td>134</td>
<td>The serum response factor SRF protect dopamine (DA) neurons in Parkinson’s disease Partially by mediate autophagy</td>
</tr>
<tr>
<td>143</td>
<td>Parkinson’s disease-associated mutations of PLA2G6 alters the membrane dynamics.</td>
</tr>
<tr>
<td>147</td>
<td>Immunohistochemical study of astrocytic markers in parkin mutations</td>
</tr>
<tr>
<td>152</td>
<td>Does endogeneous alpha-synuclein have protective property in human alpha-synuclein transgenic models?</td>
</tr>
</tbody>
</table>

Guided Poster Tour 7: Genetics
Epidemiology
Tour Leader: Baorong Zhang

Posters featured in this tour:

<table>
<thead>
<tr>
<th>Poster #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>172</td>
<td>Medical expenditure for patients with Parkinson’s disease: A nationwide population-based study</td>
</tr>
<tr>
<td>173</td>
<td>Prospective cohort study in patients with early gastric cancer for detection of prodromal Parkinson’s disease (EGC-PPD): Study rationale and protocol</td>
</tr>
<tr>
<td>175</td>
<td>12-year review of a Movement Disorders database in Singapore</td>
</tr>
<tr>
<td>177</td>
<td>Epidemiology of Parkinson’s disease among Uzbek population Epidemiology</td>
</tr>
<tr>
<td>180</td>
<td>Association of the DRD2 (CA)n and DRD3 Ser9Gly polymorphisms with Parkinson’s disease and response to dopamine agonists Genetics</td>
</tr>
<tr>
<td>184</td>
<td>Genome-wide association studies in X-linked Dystonia-Parkinsonism</td>
</tr>
<tr>
<td>185</td>
<td>Relationship between Alzheimer’s disease GWAS-linked top hits and risk of Parkinson’s disease with or without cognitive decline: A Chinese population-based study</td>
</tr>
<tr>
<td>187</td>
<td>Whole-genome sequencing and genome-wide expression profiling converge on TAF1 as a dysfunctional gene in X-linked dystonia-parkinsonism (DYT3, &quot;Lubag&quot;)</td>
</tr>
</tbody>
</table>

Guided Poster Tour 8: Non-Parkinson’s Disease Related and Other Movement Disorders
Tour Leader: Cid Diesta

Posters featured in this tour:

<table>
<thead>
<tr>
<th>Poster #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>220</td>
<td>Restless bladder in an elderly woman: an unusual variant of restless legs syndrome</td>
</tr>
<tr>
<td>117</td>
<td>Spinocerebellar Ataxia 6 in Eastern India: Some new observations</td>
</tr>
<tr>
<td>119</td>
<td>Association study between CAG repeats of PolyQ-related genes and SCA3/MJD</td>
</tr>
<tr>
<td>213</td>
<td>Cognitive profile of Filipino patients with X-linked dystonia parkinsonism</td>
</tr>
<tr>
<td>222</td>
<td>Passive ROM rehabilitation immediately following botulinum toxin injection improves outcome in post-stroke spasticity</td>
</tr>
<tr>
<td>226</td>
<td>Essential tremor in patients with Parkinson’s disease</td>
</tr>
<tr>
<td>229</td>
<td>Cardiovascular autonomic dysfunctions in essential tremor</td>
</tr>
<tr>
<td>230</td>
<td>Effect of zonisamide on post-traumatic Holmes’ tremor</td>
</tr>
</tbody>
</table>
### Guided Poster Tours

**Sunday, March 13, 2016, continued**

**Guided Poster Tour 9: Neuropharmacology**  
**Neurophysiology**  
**Neuroimaging**

Tour Leader: Yih-Ru Wu

Posters featured in this tour:

<table>
<thead>
<tr>
<th>Poster #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>201</td>
<td>Clinical correlates of striatal dopamine transporter binding in Parkinson’s disease</td>
</tr>
<tr>
<td>194</td>
<td>Regional change in glucose metabolism of essential tremor</td>
</tr>
<tr>
<td>195</td>
<td>Cerebral perfusion SPECT for Early detection of subjective memory impairment in Parkinson’s disease</td>
</tr>
<tr>
<td>196</td>
<td>The prevalence and risk factors of cerebral microbleeds in patients with Parkinson’s disease</td>
</tr>
<tr>
<td>200</td>
<td>Disrupted functional connectivity in Parkinson’s disease patients with severe olfactory dysfunction</td>
</tr>
<tr>
<td>205</td>
<td>Effect of nicotine on the pharmacokinetics of levodopa</td>
</tr>
<tr>
<td>206</td>
<td>Neuroprotective effect of Co enzyme Q10 against cognitive deficits associated with sleep deprivation and sleep debt: Possible role of oxidative stress, mitochondrial dysfunction and neuroinflammatory cascades</td>
</tr>
</tbody>
</table>

**Guided Poster Tour 10: Dystonia**  
**Drug-induced Movement Disorders**  
**Dementia**

Tour Leader: Yoshikazu Ugawa

Posters featured in this tour:

<table>
<thead>
<tr>
<th>Poster #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>160</td>
<td>Validation of a screening questionnaire for X-linked Dystonia Parkinsonism (XDP): The first phase of the population based prevalence study of XDP in Panay</td>
</tr>
<tr>
<td>163</td>
<td>Prevalence and clinical characteristics of golfer’s yips in Japan</td>
</tr>
<tr>
<td>164</td>
<td>Altered inter-hemispheric functional coordination in primary blepharospasm</td>
</tr>
<tr>
<td>165</td>
<td>Outcomes of bilateral pallidal deep brain stimulation in five patients with X-Linked Dystonia Parkinsonism (DYT3)</td>
</tr>
<tr>
<td>167</td>
<td>Validation of the proposed XDP-MDSP rating scale for the evaluation of patients with X-linked dystonia-parkinsonism (XDP)</td>
</tr>
<tr>
<td>168</td>
<td>Neuropsychiatric comorbidity and quality of life in Oromandibular Dystonia</td>
</tr>
<tr>
<td>208</td>
<td>Efficiency criteria of correction dystonia in stages of neurorehabilitation</td>
</tr>
</tbody>
</table>
Abstract Listing by Topic
Posters 1 – 116 will be presented on Saturday, March 12, 2016 from 11:30 – 12:30.

**Huntington’s disease**
1  A case of misdiagnosed Huntington’s disease: Acanthocytes in a patient with Huntington’s disease
   **FNU Ohnmar (Yangon, Myanmar)**
2  Protective effect of spermidine against 3-NP induced neurotoxicity in rats: possible antioxidant and anti-inflammatory mechanism
   **Sumit Jamwal, Puneet Kumar (Moga, India)**
3  Withdrawn by author
4  Neuroprotective potential of anti-oxidant potent fractions from Convolvulus pluricaulis Chois. in 3-Nitropropionic acid challenged rats
   **Atish Prakash, Mandeep Kaur, AN Kalia, Abu Bakar Majeed (Selangor, Malaysia)**

**Parkinsonism (secondary and parkinsonism-plus)**
6  Plethora of Parkinson’s disease - Oral health considerations with role of dentist
   **Suraj Agarwal (Agra, India)**
7  Parkinsonian signs in patients with Alzheimer’s disease is not correlated with white matter hyperintensity: a Korean study
   **Oh Dae Kwon (Daegu, Korea)**
8  Withdrawn by author
9  The importance of Ishihara Testing in early diagnosing of Parkinson disease
   **Sanjar Mirdedaev (Namangan Region, Uzbekistan)**
10  Coronary artery disease in patients with Parkinsonism syndrome with/without type 2 diabetes
    **Evgenia Shalaeva, Bakhtiyor Janabaev, Quvondiq Matmurotov, Ulugbek Kasimov, Azam Bobabekov (Tashkent, Uzbekistan)**
11  Withdrawn by author
12  Mild Parkinsonian signs in patients with cognitive dysfunction
    **Jinyoung Ahn, Seok-Jae Kang, Hee-Tae Kim (Seoul, Korea)**
13  To evaluate Molecular mechanisms associated with Manganese (Mn) induced neurotoxicity in cell and animal models: A transcriptomics approach
    **Raghunath Reddy, Rajeswara Mythri, Srinivas Bharath MM (Bangalore, India)**
14  A comparison of depressive symptoms and sleep disturbances in individuals with Parkinson’s disease and Parkinson plus syndrome
    **Rohit Verma, Kuljeet Anand (Anand, India)**
15  CSF1R mutations presenting with atypical Parkinsonism
    **Jae Hyeok Lee, Jin-Hong Shin, Gi Yeong Huh, Eun Joo Kim (Yangsan-si, Korea)**
16  Levodopa responsive secondary parkinsonism in the setting of posterior reversible encephalopathy syndrome in the postpartum period
    **Devangi Desai, Soha Desai (Anand, India)**
17  Withdrawn by author
18  Comparison of cognitive symptoms in Parkinson’s disease and Parkinson plus syndrome
    **Shaily Mina, Kuljeet Anand (New Delhi, India)**
19  Hallervorden Spatz (case report)
    **Museumeh Dashti (Isfahan, Iran)**
20  Unusual phenotype of pathologically confirmed progressive supranuclear palsy with autonomic dysfunction and cerebellar ataxia
    **Katerina Mensikova, Lucie Tuckova, Jiří Ehrmann, Petr Kanovsky (Olomouc, Czech Republic)**
21  Withdrawn by author
22  Non-motor symptoms in progressive supranuclear palsy
    **Ruwei Ou, Wei Song, Qiangqian Wei, Bei Cao, Ke Chen, Yanbing Hou, Bi Zhao, HuiFang Shang (Chengdu, Peoples Republic of China)**
23  Clinical and polysomnographic features correlates to sleep–disordered breathing in Multiple System Atrophy
    **Bei Cao, Ruwei Ou, Qian-qian Wei, Tao Hu, Bi Zhao, Hui-Fang Shang (Chengdu, Peoples Republic of China)**
24  The pathological impact of oligodendrocyte lineage cells on multiple system atrophy
    **Seiji Kaji, Takakuni Maki, Ryosuke Takahashi (Kyoto, Japan)**
25  Proteomic and Interleukin-6 (IL6), estrogen receptor beta (ESR2) gene mutation analysis in Parkinson’s disease (PD)
    **Vellingiri Balachandar, Keshavaraao Sasikala (Coimbatore, India)**
26  Gait manifestations in acquired hepatolenticular degeneration: A case report and a review of the literature
    **Karn Saksornchai, Suporn Travanichakul, Jirada Sringean, Onanong Jitkritisadakul, Roongroj Bhidayasiri (Bangkok, Thailand)**

**Parkinson’s disease: Clinical Trials**
27  Immune response mediators as a factor of Parkinson’s disease
    **Elvina Gizayitdinova, Elvina Gizayitdinova, Yuldz Musayeva, Gulnora Rakhmibayeva (Tashkent, Uzbekistan)**
Incidence of elevated lipid metabolism in patients with Parkinson’s disease
Elvina Giyazitdinova, Elvina Giyazitdinova, Yulduz Musayeva, Gulnora Rakhmibayeva (Tashkent, Uzbekistan)

The role and value of protein S100B in the blood serum of Parkinson’s disease
Rustambek Matmurodov, Khaniya Khalimova, Nilufar Rashidova (Tashkent, Uzbekistan)

Roles of combined functional catechol-O-methyltransferase genotypes in Chinese Parkinson’s disease: a cross-sectional survey
Yiwei Qian, Xiaodong Yang, Shaoqiu Jiang, Jiujian Liu, Qin Xiao (Shanghai, Peoples Republic of China)

Withdrawn by author

Clinical benefits and optimal dosage of istradefilline in Parkinson’s disease
Tetsuya Maeda, Tomomi Shinoda, Rena Muraoka, Miki Sugawara (Akita, Japan)

Neuropsychological profile of patients with Parkinson’s disease in Singapore
Jing Xu, Leonard Yeo, Christopher Chen, Raymond Seet, Erle Lim, Yan Hong Dong (Singapore)

Determining the driving ability of Parkinson’s disease patients and controls by using a computer-based 3D driving simulator
Onanong Jitkritsadakul, Soradech Krootjohn, Chusak Thanawattano, Chanawat Anan, Roongroj Bhidayasiri (Bangkok, Thailand)

Levodopa improves fatigue only in PD patients with mild or no depression
Rao Fu, Xiaoguang Luo (Shenyang, Peoples Republic of China)

Patients with Parkinson disease and vascular parkinsonism have lower urinary tract dysfunction and nocturnal polyuria, which can be ameliorated by amantadine
Tomoyuki Uchiyama, Tatuya Yamamoto, Taro Kadowaki, Keisuke Suzuki, Tomonori Yamanishi, Ryuji Sakakibara, Satoshi Kuwabara, Koichi Hirata (Shimotsuga-gun, Tochigi, Japan)

123-I-Ioflupane SPECT in combination with MIBG myocardial scintigraphy in Parkinson’s disease: A case series study
Akane Yamada, Takenobu Murakami, Yoichiro Iikuni, Akaishi Morimatsu, Akiko Shirata, Hiroshi Ito, Yoshikazu Ugawa, Kiyomi Yamane (Koriyama City, Japan)

The overview of the Japan Parkinson’s Progression Markers Initiative (J-PPMI)
Yohei Mukai, Hirohisa Watanabe, Hideki Mochizuki, Nobutaka Hattori, Ryoosuke Takahashi, Miho Murata (Tokyo, Japan)

The relationship among 123I-FP-CIT scintigraphy, 123I-MIBG cardiac scintigraphy, and olfactory function tests in Parkinson’s disease
Junya Ebina, Akiko Shinya, Kosei Hirata, Hisao Kitazono, Teruhiko Sekiguchi, Makoto Takahashi, Akira Inaba, Satoshi Orimo (Tokyo, Japan)

Attenuation of antecollis increases the blood concentration level of the levodopa in patients with the Parkinson’s disease and related disorders
Hiroyuki Todo, Yuji Saitoh, Shoko Watanabe, Yohei Mukai, Takashi Sakamoto, Miho Murata (Kodaira, Japan)

A Meta-Analysis on Safinamide as Add-on Therapy to Dopamine Agonist in Early Stage Parkinson’s disease
Gerard Raimon Saranza, Katrina Remigio, Ela Barcelon, Roland Dominic Jamora (Manila, Philippines)

Interplay between alpha and theta during working memory in patients with Parkinson’s disease
Anita Pal, Madhuri Behari, Ratna Sharma (New Delhi, India)

Ocular motor disorders and saccadic eye movements among adult Filipino Parkinson’s disease patients seen in a tertiary hospital
Anna Kharima Mindalano, Anna Lorena Chan, Criscely Go, Erwin Palisoc (Manila, Philippines)

Central cholinergic dysfunction could be associated with oropharyngeal dysphagia in early Parkinson’s disease
Wooyoung Jang (Gangneung, Korea)

Different changes in brain activities limited to certain regions related to mild cognitive impairment in early-onset and late-onset nondemented Parkinson’s disease patients
Xuetao He, Lijuan Wang, Yuhu Zhang, Jieliang Chen (Guangzhou, Peoples Republic of China)

Peripheral Neuropathy in Parkinson’s disease
Kuljeet Anand, Prashant Kumar, Jyoti Garg (Delhi, India)

The role of orexin in Parkinson’s disease: A review of article
Mehri Salari (Isfahan, Iran)
Abstract Listing by Topic

Posters 1 – 116 will be presented on Saturday, March 12, 2016 from 11:30 – 12:30.

49 Parkinson’s disease treatment as a factor of cardiac pathology
Elvina Giyazitdinova, Elvina Giyazitdinova, Yulduz Musayeva (Tashkent, Uzbekistan)

50 Dopaminergic therapy: on a number of complications as increasing of libido in patients with Parkinson’s disease and Parkinson’s syndrome
Sanjar Mirdedaev (Namangan Region, Uzbekistan)

51 Combined levodopa carbidopa with Entacapone improves the motor complications in advanced Parkinson’s disease
Md. Ashraf Ali (Dhaka, Bangladesh)

52 Neuroprotective effect of apocyanin, a NADPH oxidase inhibitor in lipopolysaccharide induced Parkinson’s disease model
Bimla Nehru (Chandigarh, India)

53 Withdrawn by author

54 Effects of Single Lipopolysaccharide Preconditioning on Rat model for Parkinson’s disease
Mojtaba Golpich, Elham Amini, Zahurin Binti Mohamed, Raymond Azman Ali, Norlinah Ibrahim, Abolhassan Ahmadiani (Petaling Jaya, Malaysia)

55 Novel HDAC1/2 isoform-specific inhibitor K560 ameliorates MPP+/MPTP-mediated experimental Parkinson’s disease
Chi-Jing Choong, Tsutomu Sasaki, Hideki Hayakawa, Toru Yasuda, Kousuke Baba, Yoshiyuki Hirata, Shinichi Uesato, Hideki Mochizuki (Osaka, Japan)

56 Efficacy and tolerability of levetiracetam in the management of levodopa-induced dyskinesia in Parkinson’s disease: A meta-analysis
Virulo Marianito, Anthony Piano, Artemio Roxas (Pasig City, Philippines)

57 The efficacy and safety of Zonisamide as adjunctive therapy in Parkinson’s disease: a meta-analysis
Katrina Remigio, Gerard Raimon Saranza, Roland Dominic Jamora (Manila, Philippines)

Parkinson’s disease: Neurorehabilitation

58 Risk and adverse outcomes of fractures in patients with Parkinson’s disease: Two nationwide studies
Yi-Chun Chou, Chien-Chang Liao (Taichung, Taiwan)

59 Withdrawn by author

60 The Effect of the Pilates method on the motor symptoms, depression and quality of life of Filipino patients with Parkinson’s disease
Juan Miguel Bautista, Arlene Ng, Rosemarie Malla-ao (Quezon City, Philippines)

61 The relationship between body composition and postural instability in people with idiopathic Parkinson’s disease
Abdulkareem Diab, Leigh Hale (Baghdad, Iraq)

62 Gait-Aid for Freezing Gait of Parkinson’s disease
Ho-Won Lee, Kyunghun Kang, Pan-Woo Ko (Gainesville, FL, USA)

63 Effect of gait and balance training on Parkinson’s disease patients after Bilateral STN-DBS.
Venkata Padma Kagita, Rupam Borgohain, Rukmini Kandadai, Anel Puligopu, Naveen Balne (Hyderabad, India)

64 Withdrawn by author

65 Screening of Vitamin D receptor (VDR) and Dopamine beta hydroxylase gene polymorphism and susceptibility to Parkinson’s disease in South Indian Population
Dhivya Venkatesan (Chennai, India)

Parkinson’s disease: Non-motor phenotypes

66 Prevalence and associations for depression in patients with Parkinson’s disease: A Sri Lankan experience
Tharuka Herath, Milinda Withana, Chathuraka Rodrigo, Ranjanie Gamage, Chanika Gamge (Kandy, Sri Lanka)

67 Validation of the Seoul-instrumental activity daily living in the detection of dementia in Parkinson disease
Sang Jin Kim, Eun Joo Chung (Busan, Korea)

68 Clinical correlates of depression and anxiety in patients with Parkinson’s disease
Hasmik Hambardzumyan, Hovhannes Manvelyan (Yerevan, Armenia)

69 Non-Motor Symptoms in Parkinson’s patients: the PALS (Early Parkinson’s Disease Longitudinal Singapore) Study
Samuel Ng, Hannah Heng, Zheyu Xu, Kay Yaw Tay, Wing Lok Au, Louis Tan (Singapore)

70 Food-induced rhinorrhea in Parkinson’s disease
Osamu Kano, Renpei Sengoku, Shigeo Murayama, Yasuo Iwasaki (Tokyo, Japan)

71 Orthostatic hypotension and cardiac sympathetic denervation in Parkinson disease patients with REM sleep behavioral disorder
Kwang-Soo Lee, Joong-Seok Kim (Seoul, Korea)

72 Degree cognitive impairment in Parkinson’s disease depending on the level of protein S100B in the blood serum
Rustambek Matmurodov, Khanifa Khalimova (Tashkent City, Uzbekistan)
Abstract Listing by Topic

Posters 1 – 116 will be presented on Saturday, March 12, 2016 from 11:30 – 12:30.

73 Dopamine Agonists Withdrawal Syndrome in patients with Parkinson’s disease in a rural movement disorders clinic in Western India
Soaham Desai, Devangi Desai (Anand, India)

74 Anemia precedes the onset of motor symptoms of Parkinson’s disease: a population-based cohort
Chientai Hong, Lung Chan, Li Nien Chen (New Taipei City, Taiwan)

75 Lateral Geniculate Atrophy in Parkinson’s with Visual Hallucination
Jee-Young Lee, Eun Jin Yun, Yu Kyeong Kim, Woong-Woo Lee, Beomseok Jeon (Seoul, Korea)

76 Apathy and striatal dopamine defects in non-demented patients with Parkinson’s disease
Su Jin Chung, Jae Jung Lee, Jee Hyun Ham, Phil Hyu Lee, Young Sohn (Seoul, Korea)

77 Evaluation of olfactory dysfunction in Parkinson’s disease in Northern Sri Lanka
Ajantha Keshavaraj, Sorubiga Kunathilagam, Gajalaksan Balachandran (Colombo, Sri Lanka)

78 Cognitive behavioral therapy for Japanese PD patients with depression
Issei Shinmei, Miho Murata, Masaru Horikoshi (Kodaira, Japan)

79 Intestinal dysbiosis and lowered serum lipopolysaccharide-binding protein in Parkinson’s disease
Satoru Hasegawa, Sae Goto, Hirokazu Tsuji, Tatsuya Okuno, Takashi Asahara, Koji Nomoto, Akhide Shibata, Yoshio Fujisawa, Akira Okamoto, Kinji Ohno, Masaaki Hirayama (Nagoya City, Japan)

80 EMG variance and dream-enactment behavior during polysomnography in Parkinson’s disease
Yun Shen, Kangping Xiong, Cheng Jie Mao, Chun-Feng Liu (Suzhou, Peoples Republic of China)

81 Assessment of motor imaginary of gait by timed up and go test and cognitive impairment in Parkinson’s disease
Yasuko Kuroha, Arika Hasegawa, Takashi Tani, Nae Matsubara, Takeshi Ikeuchi, Ryoko Koike (Niigata, Japan)

82 The 3-second rule in Parkinson’s disease: A synchronized tapping study
Shin-ichi Tokushige (Tokyo, Japan)

83 Withdrawn by author

84 Disruption of circadian rhythm function and antioxidation via SIRT1-BMAL1 pathway in 6-OHDA induced Parkinson’s disease model
Yali Wang, Siyue Li, Chun-feng Liu (Suzhou, Peoples Republic of China)

85 Long-term administration of L-DOPA accelerates the disorders of circadian rhythm in 6-OHDA induced PD model
Siyue Li, Yali Wang, Chunfeng Liu (Suzhou, Peoples Republic of China)

86 Progression of non-motor symptoms in Parkinson’s disease among different age populations: A two years follow-up study
Ruwei Ou, Jing Yang, Bei Cao, Qianqian Wei, Ke Chen, Xueping Chen, Bi Zhao, Ying Wu, Wei Song, HuiFang Shang (Chengdu, Peoples Republic of China)

87 Retinal nerve fiber layer thinning: a window into rapid eye movement sleep behavior disorders in Parkinson’s disease
Zijiao Yang, Cheng Jie Mao, Jing Wei, Jin-ru Zhang, Yun Shen, Jie Li, Ya-ping Yang, Chunfeng Liu (Suzhou, Peoples Republic of China)

88 Olfaction, constipation onset time and axial impairment of Parkinson’ disease: can we identify clinical phenotypes?
Yan Dai, Chunfeng Liu (Soochow, Peoples Republic of China)

89 Olfactory deficits in the cognitive impaired de novo patients with Parkinson’s disease
Jong Sam Baik (Seoul, Korea)

90 The regulation of ASIC1a on dopamine release and its implication in the pathogenesis of Parkinson’s disease
Jing Yang, Sha Liu, Fen Wang, Chun-feng Liu (Suzhou, Peoples Republic of China)

91 Predictive value of motor and non-motor symptoms for the assessment of dementia and REM sleep behavior disorders (RBD) in Parkinson’s disease patients (drug naive and on medication)
Leny Mathew, Suresh Kumar, Suresh Kumar Stephen Abraham, SSK Ayyar (Pathanamthitta, India)

92 Classification of subtypes/phenotypes of Parkinson’s disease, a study from a tertiary teaching hospital in south India
Leny Mathew, Suresh Kumar, Suresh Kumar Stephen Abraham, SSK Ayyar (Pathanamthitta, India)

93 A gene for risk taking: effect of genotypic variants on decision making and impulsivity in Parkinson’s disease.
Roopa Rajan, Soumya Krishnamoorthy, Syam Krishnan, Gangadhara Sarma, Asha Kishore (Kerala, India)

94 Subjective and Objective evaluation of bowel movement among Parkinson’s disease, REM sleep behavior disorder, and control
Takashi Nomura, Kenjiakashima (Yonago, Japan)
Abstract Listing by Topic

Posters 1 – 116 will be presented on Saturday, March 12, 2016 from 11:30 – 12:30.

Parkinson’s disease: Phenomenology
95 Sleep disorders as a common manifestation of Parkinson’s disease
Elvina Giyazitdinova, Elvina Giyazitdinova, Yulduz Musayeva (Tashkent, Uzbekistan)
96 Relation of CADASIL syndrome to etiology and pathogenesis of vascular Parkinsonism
Elvina Giyazitdinova, Elvina Giyazitdinova, Yulduz Musayeva (Tashkent, Uzbekistan)
97 Gait analysis of Parkinson’s disease patients with freezing of gait
Su-Yun Lee, Sang-Myung Cheon, Jae Woo Kim (Busan, Korea)

Parkinson’s disease: Quality of Life/Caregiver burden
98 Withdrawn by author
99 Parkinson’s Disease and the frequent reasons for emergency admission in Metropolitan Medical Center; a 2 year retrospective study
Kenneth Wong, Criscely Go (Manila, Philippines)
100 Beneficial role of voice inter-relating process and OM mantra enchanting in Parkinson’s disease patients in south Delhi metro population
Vinod Sharma (Delhi, India)
101 Levodopa-Carbidopa Intestinal Gel: The naso-jejunal phase, a redundant convention?
Nirosen Vijiaratnam, Sarah Hewer, Sue Varley, Eldho Paul, Kelly Bertram, Will Lee, David Williams (Melbourne, Australia)
102 Influence of tremor on quality of life of patients with Parkinson disease
Ziyoda Akbarkhodjaeva, Gulnora Rakhmibayeva (Tashkent, Uzbekistan)
103 Increased Risk of Depression in Patients with Parkinson Disease: A Nationwide Cohort Study
Chien-Chang Liao, Fung-Chang Sung (Taipei, Taiwan)
104 Fall and near fall risks in ambulatory Filipino Patients with Parkinson’s disease
Jemellee Cano, Raymond Rosales (Quezon City, Philippines)
105 Withdrawn by author
106 Non-motor features among motor subtypes in newly diagnosed Parkinson’s disease patients: a cohort study from Southwest China
Ying Wu (Chengdu, Peoples Republic of China)

Parkinson’s disease: Rating scales
107 Parkinson’s disease risk score (PDRS) for Parkinson’s disease screening in aging population: Effect of yoga and Meditation
Vinod Sharma (Delhi, India)
108 Prevalence of Impulse Control Disorders among Adult Filipino Patients with Idiopathic Parkinson’s Disease seen at Jose R. Reyes Memorial Medical Center Preliminary Results
Jan Kristoper De Guzman, Criscely Go, Archie Yap (Manila, Philippines)
109 Treatment and diagnosis with the use of neuropsychological scale in patients with posttraumatic subcortical Parkinsonian dementia
Nodirjon Sokhibnazarov (Tashkent, Uzbekistan)
110 A novel patient diary for assessment of motor fluctuations and drug efficacy in Parkinson’s disease
Masahiro Nagai, Noriko Nishikawa, Hirotaka Iwaki, Rina Ando, Hayato Yabe, Masahiro Nomoto (Ehime, Japan)
111 Lower bone mineral density in Patients with Parkinson’s disease: a cross-sectional study from Chinese Mainland
Huimin Gao (Guangzhou, Peoples Republic of China)

Surgical Therapy: Parkinson’s disease
112 Outcomes after non-neurological surgery in patients with Parkinson’s disease: A nationwide matched cohort study
Chien-Chang Liao, Ta-Liang Chen (Taipei, Taiwan)
113 Valproic acid improved hypersexuality after surgery of subthalamic nucleus deep brain stimulation in a patient with Parkinson’s disease: A case report.
Taro Kadowaki, Kenichi Hashimoto, Tomoyuki Uchiyama, Koichi Hirata (Mibu, Japan)
114 The mechanisms of the STN or the GPi stimulation to striatal neurons response.
Asuka Nakajima, Yasushi Shimo, Takayuki Jo, Takanori Uka, Nobutaka Hattori (Tokyo, Japan)
115 Impulse control disorders in Parkinson’s disease - Impact of deep brain stimulation and other factors
Rupam Borghain, Rukmini Kandadai, Aneel Puligopu, K Vani, Shaik Jabeen, Meena Kanikannan (Hyderabad, India)
116 “Uneven targets” strategy in deep brain stimulation for Parkinson’s disease with unilateral dystonia
Takayuki Jo, Satoko Sekimoto, Genko Oyama, Asuka Nakajima, Yasushi Shimo, Madoka Nakajima, Atsushi Umemura, Masanobu Ito, Hajime Arai, Nobutaka Hattori (Tokyo, Japan)
Abstract Listing by Topic

Posters 117 – 233 will be presented on Sunday, March 13, 2016 from 11:30 – 12:30.

Ataxia

117 Spinocerebellar Ataxia 6 in Eastern India: Some new observations
Kalyan Bhattacharyya, Debabrata Pulai, Debsankar Guin, Anindita Joardar, Swarnava Ray, Atanu Biswas, Alok Pandit, Gautam Ganguly (Kolkata, India)

118 Clinical phenotype of patients with SCA 12.
Aakash Shetty, Pettarusp Wadia (Mumbai, India)

119 Association study between CAG repeats of PolyQ-related genes and SCA3/MJD
Hong Jiang, Zhao Chen, Caifa Zheng, Beisha Tang (Changsha City, Peoples Republic of China)

120 Is heart less frequently involved in Indian Friedreich’s ataxia patients: A genotype phenotype correlation study?
Achal Srivastava, Inder Mudila, Mohammed Faruq, Sunil Shakya, Varun Suroliya, Garima Shukla, Vinay Goyal, MV Padma, Madhuri Behari (New Delhi, India)

Basic Science

121 Comprehensive research on the roles of neurotransmitters in pathogenesis of Movement Disorders
Babak Khodaie (Tehran, Iran)

122 Generation of naivetricop induced pluripotent stem cells from Parkinson’s disease patients for high efficiency genetic manipulation
Jiali Pu, Zhixing Hu, Houbo Jiang, Ping Zhong, Baorong Zhang, Jian Feng (Hangzhou, Peoples Republic of China)

123 Withdrawn by author

124 Alternative mitophagy suppresses the development of Parkin-related Parkinson’s disease
Jin Sung Park, Brianada Koentjoro, Carolyn Sue (St. Leonards, Australia)

125 Forebrain-specific knockout of ESCRT-0/Hrs disrupts protein quality control and facilitates ER stress-mediated neurodegeneration via apoptotic and necrotic pathways
Ryuuji Oshima, Takafumi Hasegawa, Keiichi Tamai, Atsushi Takeda, Nobuyuki Tanaka, Masashi Aoki (Sendai, Japan)

126 Microglia P2Y6 receptor is related to Parkinson’s disease
Xiaodong Yang, Yue Lou, Xueping Wang, Guidong Liu, Yiwei Qian, Jianqing Ding, Shengdi Chen, Qin Xiao (Shanghai, Peoples Republic of China)

127 The activity of protein S100B in the blood serum depending on the age of patients and duration of Parkinson’s disease
Rustambek Matmurovod, Khanifa Khalimova, Nilufar Rashidova (Tashkent City, Uzbekistan)

128 Effects of bisphenol A exposure during gestation and lactation on the emotional behavior and the content of brain neurotransmitters in rat offspring
Mridul Mishra, Versha Parcha (Dehradun, India)

129 The effects of different concentrations of nanoliposome on the fibrillation of alpha-synuclein
Farhang Aliakbari, Dina Morshedl, Ali Akbar Shabani, Hassan Bardania, Carolyn Sue, Amir Tayarzan Marvian, Seyed Abbas Shojaosadati, Ali Akbar Saboury (Tehran, Iran)

130 Methodical recommendation for experimental modeling of parkinsonian syndrome in laboratory animals under antiparkinsonian medicaments.
Djakhangir Tursunov (Tashkent, Uzbekistan)

131 Rotenone model of Parkinson’s syndrome in experimental animals
Djakhangir Tursunov (Tashkent, Uzbekistan)

132 The role of cathepsin L involved in the activation of microglia and Parkinson’s disease
Shaoqing Xu, Xiaodong Yang, Hui Zhang, Yiwei Qian, Qin Xiao (Shanghai, Peoples Republic of China)

133 Tremor model caused by oxotremorine
Eldor Kasimov (Tashkent, Uzbekistan)

134 The serum response factor SRF protect dopamine (DA) neurons in Parkinson’s disease Partially by mediate autophagy
Xiao-ju Cheng (Suzhou, Peoples Republic of China)

135 Main evaluation methods of medicaments which has an antiparkinsonian activity by experimental way.
Fazliddin Dustov (Tashkent, Uzbekistan)

136 Evaluation of L-Dopa induced dyskinesia by scale of abnormal involuntary movements
 Akmal Ikramov (Tashkent, Uzbekistan)

137 Decreased glucocerebrosidase enzyme activity inhibits dopamine release from SH-SY5Y cells
Yutaka Oji, Taku Hatano, Nobutaka Hattori (Tokyo, Japan)

138 Umbilical cord lining-derived induced pluripotent stem cells as a novel source for cell replacement therapy of Parkinson’s disease
Chou Chai, Ru Ong, Cheng Zhang, Bing Chai, Li Qiu, Moogaambikai Thangaveloo, Dejie Yu, Tuck Soong, Beng Ang, Soo Tang, Li Zeng, Eng-King Tan, Toan Phan, Kah-Leong Lim (Singapore)
### Abstract Listing by Topic

**Posters 117 – 233 will be presented on Sunday, March 13, 2016 from 11:30 – 12:30.**

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>139</td>
<td>The effect of HSA protein on the alpha-synuclein aggregation kinetics</td>
<td>Hossein Mohammad-Beigi, Dina Morshed, Seyed Abbas Shojaosadati, Gunna Christiansen, Daniel Otzen (Tehran, Iran)</td>
</tr>
<tr>
<td>140</td>
<td>Differential developmental apoptosis and apoptotic markers in 1-Methyl-4-Phenyl 1,2,3,6-Tetrahydropyridine (MPTP) resistant and susceptible mice strains and their crossbreds</td>
<td>Yarreiphang Haorei, Vidyadhara D J, Trichur Raju, Phalguni Alladi (Bangalore, India)</td>
</tr>
<tr>
<td>141</td>
<td>Admixed F1 progeny of Two Mice Strains with differential susceptibility to 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) have a better Nigral Dopaminergic Phenotype</td>
<td>Phalguni Alladi, Vidyadhara D J, Yarreiphang Haorei, P.L. Abhilash, Trichur Raju (Bangalore, India)</td>
</tr>
<tr>
<td>142</td>
<td>Withdrewn by author</td>
<td></td>
</tr>
<tr>
<td>143</td>
<td>Parkinson’s disease-associated mutations of PLA2G6 alters the membrane dynamics.</td>
<td>Akio Mori, Taku Hatano, Yuzuru Imai, Yutaka Oji, Shin-ichiro Kubo, Kei Yamamoto, Makoto Murakami, Nobutaka Hattori (Tokyo, Japan)</td>
</tr>
<tr>
<td>144</td>
<td>Withdrewn by author</td>
<td></td>
</tr>
<tr>
<td>145</td>
<td>The structure analysis for alpha-synuclein and Lewy bodies of Parkinson’s disease patients with synchrotron radiation</td>
<td>Katsuya Araki, Naoto Yagi, Rie Nakatani, Hideki Hayakawa, Kousuke Baba, Yuji Goto, Hideki Mochizuki (Osaka, Japan)</td>
</tr>
<tr>
<td>146</td>
<td>Contra-directional coupling of Nur77 and Nurr1 in Neurodegeneration: A novel mechanism for Memantine-induced anti-inflammation and anti-mitochondrial impairment</td>
<td>Jing Zou, Xiaobo Wei, Qing Wang (Guangzhou, Peoples Republic of China)</td>
</tr>
<tr>
<td>147</td>
<td>Immunohistochemical study of astrocytic markers in parkin mutations</td>
<td>Masayoshi Kanou (Tokyo, Japan)</td>
</tr>
<tr>
<td>148</td>
<td>Influence of CD200 on inhibiting the inflammatory response by regulating the KATP channel of MG cells in PD mice</td>
<td>Min Ye (Nanjing, Peoples Republic of China)</td>
</tr>
<tr>
<td>149</td>
<td>Nur77 involved in ERstress-induced apoptosis and autophagic cell death in 6-OHDA lesioned PC12 cell</td>
<td>Huimin Gao (Guangzhou, Peoples Republic of China)</td>
</tr>
<tr>
<td>150</td>
<td>Withdrewn by author</td>
<td></td>
</tr>
<tr>
<td>151</td>
<td>Glucocerebrosidase deficiency promotes the propagation of α-synuclein pathology</td>
<td>Shinya Okuda, Norihito Uemura, Ryosuke Takahashi (Kyoto, Japan)</td>
</tr>
<tr>
<td>152</td>
<td>Does endogeneous alpha-synuclein have protective property in human alpha-synuclein transgenic models?</td>
<td>Masanori Sawamura (Kyoto, Japan)</td>
</tr>
<tr>
<td>153</td>
<td>Purification of Drosophila-Omi protein from bacterial expression and production of anti-Drosophila-Omi polyclonal antibody from mouse</td>
<td>Saidul Islam, Md. Rahman, Hyeon Kim, Seong Hong (Jeonju, Korea)</td>
</tr>
<tr>
<td>154</td>
<td>A case of facial tics and hemichorea in human immunodeficiency virus infection with toxoplasma encephalitis</td>
<td>Anissa Anandatia, Ahmad Alwahdy, Darma Imran, Riwanti Estiasari (Bekasi, Indonesia)</td>
</tr>
<tr>
<td>155</td>
<td>A case report on choreiform movement following Rivastigmine Patch 13.3 mg/24 hours for Alzheimer’s disease: Perspective in the Movement Disorders spectrum following use of cholinesterase inhibitors</td>
<td>Raymond Rosales, Maria Cristina Diaz, Julie Ann Kristy Torres (Manila, Philippines)</td>
</tr>
<tr>
<td>156</td>
<td>Withdrewn by author</td>
<td></td>
</tr>
<tr>
<td>157</td>
<td>Withdrewn by author</td>
<td></td>
</tr>
<tr>
<td>158</td>
<td>Tardive dyskinesia in patients with depressive disorder treated with flupentixol-melitracin - results from a 12-month, prospective, open study under naturalistic conditions in Bangladesh</td>
<td>Rashimul Haque, Kaniza Kabir (Dhaka, Bangladesh)</td>
</tr>
<tr>
<td>159</td>
<td>An unusual case of primary non-acquired Hemidystonia</td>
<td>Shyam Jaiswal, Muralidhar Reddy, Subhendu Parida (Hyderabad, India)</td>
</tr>
<tr>
<td>160</td>
<td>Validation of a Screening Questionnaire for X-linked Dystonia Parkinsonism (XDP): The First Phase of the Population Based Prevalence Study of XDP in Panay</td>
<td>Jose Danilo Diestro, Paul Matthew Pasco, Lillian Lee (Manila, Philippines)</td>
</tr>
<tr>
<td>161</td>
<td>Treatment of dystonia and tremors in Parkinson’s disease</td>
<td>Sanjay Jaiswal (Kota, India)</td>
</tr>
</tbody>
</table>
### Abstract Listing by Topic

**Posters 117 – 233 will be presented on Sunday, March 13, 2016 from 11:30 – 12:30.**

<table>
<thead>
<tr>
<th>Posters</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>162</td>
<td>Long-term improvement of musician’s and writer’s focal dystonia after ventrooral thalamotomy</td>
<td>Takaomi Taira, Shiro Horisawa (Tokyo, Japan)</td>
</tr>
<tr>
<td>163</td>
<td>Prevalence and Clinical Characteristics of Golfer’s Yips in Japan</td>
<td>Yasufumi Gon, Masahito Mihara, Sadahito Kawamura, Ken Nakata, Hideki Mochizuki (Saitama, Japan)</td>
</tr>
<tr>
<td>164</td>
<td>Altered inter-hemispheric functional coordination in primary blepharospasm</td>
<td>Jing Yang, ChunYan Luo, Song Wei, Qianglian Wei, Ruwei Ou, Yanbing Hou, Bi Zhao, QiYong Gong, HuiFang Shang (Chengdu, Peoples Republic of China)</td>
</tr>
<tr>
<td>165</td>
<td>Outcomes of bilateral pallidal deep brain stimulation in 5 patients with X-Linked Dystonia Parkinsonism (DYT3)</td>
<td>Jose Francisco Aguilar, Theodor Vesagas, Roland Dominic Jamora, Rosalia Teleg, Lillian Lee (San Juan City, Philippines)</td>
</tr>
<tr>
<td>166</td>
<td>The Effects of Botulinum Toxin in Oromandibular Dystonia, A Meta-analysis</td>
<td>Ria Monica Asuncion, Raymond Rosales (Manila, Philippines)</td>
</tr>
<tr>
<td>167</td>
<td>Validation of the proposed XDP-MDSP rating scale for the evaluation of patients with X-linked dystonia-parkinsonism (XDP)</td>
<td>Paul Matthew Pasco, Lillian Lee, Roland Dominic Jamora, Cid Czarina Diesta, Arlene Ng, Rosalia Teleg, Criscely Go, Raymond Rosales, Hubert Fernandez (Manila, Philippines)</td>
</tr>
<tr>
<td>168</td>
<td>Neuropsychiatric comorbidity and quality of life in oromandibular dystonia</td>
<td>Vinay Goyal, Rai Neha, Kumar Nand, Shukla Behari (New Delhi, India)</td>
</tr>
<tr>
<td>169</td>
<td>Case study of sporadic multiple system atrophy at a young age</td>
<td>Elvina Giyazidinova, Elvina Giyazidinova, Yulduz Musayeva (Tashkent, Uzbekistan)</td>
</tr>
<tr>
<td>170</td>
<td>Delayed hits and misses in the diagnosis of Parkinson’s disease</td>
<td>Criscely Go (Manila, Philippines)</td>
</tr>
<tr>
<td>171</td>
<td>Withdawn by author</td>
<td></td>
</tr>
<tr>
<td>172</td>
<td>Medical expenditure for patients with Parkinson’s disease: a nationwide population-based study</td>
<td>Yi-Chun Chou, Chien-Chang Liao, Ta-Liang Chen (Taichung, Taiwan)</td>
</tr>
<tr>
<td>173</td>
<td>Prospective cohort study in patients with Early Gastric Cancer for detection of Prodromal Parkinson Disease (EGC-PPD): study rationale and protocol</td>
<td>Chae Won Shin, Han-Kwong Yang, SungHye Park, Hyuk-Joon Lee, Sun Im Kim, Woong-Woo Lee, Hyeyoung Park, Arun Kim, Han-Joon Kim, Beomseok Jeon (Seoul, Korea)</td>
</tr>
<tr>
<td>174</td>
<td>Withdrawn by author</td>
<td></td>
</tr>
<tr>
<td>175</td>
<td>12-Year Review of a Movement Disorders Database in Singapore</td>
<td>Irene Seah, Samuel Ng, Wei Li, Hwee Lan Ng, Kay Yaw Tay, Wing Lok Au, Louis Tan (Singapore)</td>
</tr>
<tr>
<td>176</td>
<td>Epidemiology of Parkinson’s disease in Ukraine in 2014</td>
<td>Yevgen Trufanov, Natalia Svyrydova, Anatoliy Galusha, Oleksiy Popov, Genadiy Chupryna (Kyiv, Ukraine)</td>
</tr>
<tr>
<td>177</td>
<td>Epidemiology of Parkinson’s disease among Uzbek population</td>
<td>Navruza Tolibova, Mukhlima Khanova, Oybek Turgunkhujaev (Tashkent, Uzbekistan)</td>
</tr>
<tr>
<td>178</td>
<td>LINE-1 expression and correlation with methylation status in rat brain</td>
<td>Somnath Mukherjee, K.C Upadhayaya, Deepak Sharma (New Delhi, India)</td>
</tr>
<tr>
<td>179</td>
<td>Role of DJ-1 promoter variants in Parkinson’s disease pathogenesis</td>
<td>Prosenjit Pal, Tamal Sadhukhan, Shyamal Das, Kunal Ray, Jharna Ray (Kolkata, India)</td>
</tr>
<tr>
<td>180</td>
<td>Association of the DRD2 (CA)n and DRD3 Ser9Gly polymorphisms with Parkinson’s disease and response to dopamine agonists</td>
<td>Shaoqing Xu, Jiujiang Liu, Xiaodong Yang, Yiwei Qian, Qin Xiao (Shanghai, Peoples Republic of China)</td>
</tr>
<tr>
<td>181</td>
<td>Withdrawn by author</td>
<td></td>
</tr>
<tr>
<td>182</td>
<td>Analysis the relationship between behavioral and molecular genetics in stroke patients - A case control study</td>
<td>R. Chandirasekar, K Murugan (Coimbatore, India)</td>
</tr>
<tr>
<td>183</td>
<td>Withdawn by author</td>
<td></td>
</tr>
<tr>
<td>184</td>
<td>Genome-wide association studies in X-linked Dystonia-Parkinsonism</td>
<td>Gerard Raimon Saranza, Aloysius Domingo, Paul Matthew Pasco, Roland Dominic Jamora (Manila, Philippines)</td>
</tr>
</tbody>
</table>

**Epidemiology**

- 169 Case study of sporadic multiple system atrophy at a young age  
  - Elvina Giyazidinova, Elvina Giyazidinova, Yulduz Musayeva (Tashkent, Uzbekistan)
- 170 Delayed hits and misses in the diagnosis of Parkinson’s disease  
  - Criscely Go (Manila, Philippines)
- 171 Withdrawn by author
- 172 Medical expenditure for patients with Parkinson’s disease: a nationwide population-based study  
  - Yi-Chun Chou, Chien-Chang Liao, Ta-Liang Chen (Taichung, Taiwan)

**Genetics**

- 178 LINE-1 expression and correlation with methylation status in rat brain  
  - Somnath Mukherjee, K.C Upadhayaya, Deepak Sharma (New Delhi, India)
- 179 Role of DJ-1 promoter variants in Parkinson’s disease pathogenesis  
  - Prosenjit Pal, Tamal Sadhukhan, Shyamal Das, Kunal Ray, Jharna Ray (Kolkata, India)
- 180 Association of the DRD2 (CA)n and DRD3 Ser9Gly polymorphisms with Parkinson’s disease and response to dopamine agonists  
  - Shaoqing Xu, Jiujiang Liu, Xiaodong Yang, Yiwei Qian, Qin Xiao (Shanghai, Peoples Republic of China)
- 181 Withdrawn by author
- 182 Analysis the relationship between behavioral and molecular genetics in stroke patients - A case control study  
  - R. Chandirasekar, K Murugan (Coimbatore, India)
- 183 Withdrawn by author
- 184 Genome-wide association studies in X-linked Dystonia-Parkinsonism  
  - Gerard Raimon Saranza, Aloysius Domingo, Paul Matthew Pasco, Roland Dominic Jamora (Manila, Philippines)
Abstract Listing by Topic

Posters 117 – 233 will be presented on Sunday, March 13, 2016 from 11:30 – 12:30.

185 Relationship between Alzheimer’s disease GWAS-linked top hits and risk of Parkinson’s disease with or without cognitive decline: A Chinese population-based study
Jifeng Guo, Xinxiang Yan, BeiSha Tang (Changsha, Peoples Republic of China)

186 Genetic identification is critical for the diagnosis of Parkinsonism: A Chinese pedigree with onset of Parkinsonism
Jifeng Guo, Lu Shen, Xinxiang Yan, BeiSha Tang (Changsha, Peoples Republic of China)

187 Whole-genome sequencing and genome-wide expression profiling converge on TAF1 as a dysfunctional gene in X-linked dystonia-parkinsonism (DYT3, “Lubag”)
Aloysius Domingo, Ana Westenberger, Karen Gruetz, Roland Dominic Jamora, Paul Matthew Pasco, Raymond Rosales, Lilian Lee, Christine Klein (Luebeck, Germany)

Lewy Body Dementia and other dementias in movement disorders

188 Clinical usefulness of F18-FP-CIT PET/CT in possible dementia with Lewy bodies
Jinyoung Ahn, Hee-Tae Kim, Jae-Hyeok Heo (Seoul, Korea)

Myoclonus

189 Familial cortical myoclonic tremor with epilepsy in Chinese population: Clinical and neurophysiologic features in nine pedigrees from China
Zhiding Cen, Chunping Huang, Houmin Yin, Fei Xie, Xingjiao Lu, Zhiyuan Ouyang, Yuting Lou, Xia Qiu, Zhongjin Wang, Jianfeng Xiao, Meiping Ding, Wei Luo (Hangzhou, Peoples Republic of China)

190 Focal myoclonus-dystonia of the upper extremity secondary to a lesion of cerebellum: A case report
Guangxun Shen, Beomseok Jeon, Guangxian Nan (Changchun, Peoples Republic of China)

191 Fahr’s Syndrome in a Filipino female with hearing loss and polycystic ovaries: A case report
Pariessa Dadgardoust (Quezon City, Philippines)

Neuroimaging

192 Withdrawn by author

193 Transcranial sonography of the substantia nigra and its correlation with iron metabolism and c-reactive protein in Parkinson’s disease
Xiaodong Yang, Juijiang Liu, Yiwei Qian, Shaoqing Xu, Qin Xiao (Shanghai, Peoples Republic of China)

194 Regional change in glucose metabolism of essential tremor
In-Uk Song, Kwang-Soo Lee, Yong-An Chung (Yong-In, Korea)

195 Cerebral perfusion SPECT for early detection of subjective memory impairment in Parkinson’s disease
Kwang-Soo Lee, In-Uk Song, Jeong Wook Park (Seoul, Korea)

196 The prevalence and risk factors of cerebral microbleeds in patients with Parkinson’s disease
Kazu Yamashiro, Ryota Tanaka, Yasunobu Hoshino, Taku Hatano, Kenya Nishioka, Nobutaka Hattori (Tokyo, Japan)

197 Magnetic resonance imaging markers of Parkinson’s disease: examining the combined use of DTI and ASL
Huimin Gao (Guangzhou, Peoples Republic of China)

198 Effect of olfactory impairment and white matter hyperintensities on cognition in Parkinson’s disease
Phil Hyu Lee, Jee Hyun Ham, Young Sohn (Seoul, Korea)

199 Dual Time Point F-18 FP-CIT PET Imaging in Idiopathic Parkinson’s Disease
Yong-An Chung, In-Uk Song (Incheon, Korea)

200 Disrupted functional connectivity in Parkinson’s disease patients with severe olfactory dysfunction
Hirohisa Watanabe, Epifanio Bagarinao, Noritaka Yoneyama, Kazuya Kawabata, Masahisa Katsuno, Gen Sobue, Kazuhiro Hara (Nagoya, Japan)

201 Clinical correlates of striatal dopamine transporter binding in Parkinson’s disease
Shigeki Hirano, Hongliang Li, Shogo Furukawa, Yoshikazu Nakano, Kazuho Kojima, Ai Ishikawa, Hong Tai, Takuro Horikoshi, Takashi Uno, Satoshi Kuwabara (Chiba, Japan)

Neuropharmacology

202 Withdrawn by author

203 Withdrawn by author

204 The efficacy and safety of Zonisamide as adjunctive therapy in Parkinson’s disease: A meta-analysis
Katrina Remigio, Gerard Raimon Saranza (Manila, Philippines)

205 Effect of nicotine on the pharmacokinetics of levodopa
Win Thiri Kyaw, Masahiro Nagai, Noriko Nishikawa, Hirotaka lwaki, Masahiro Nomoto (Tohon, Japan)

206 Neuroprotective effect of Co enzyme Q10 against cognitive deficits associated with sleep deprivation and sleep debt: Possible role of Oxidative Stress, Mitochondrial Dysfunction and Neuroinflammatory cascades
Priyanka Chanana, Anil Kumar (Chandigarh, India)
Abstract Listing by Topic

Posters 117 – 233 will be presented on Sunday, March 13, 2016 from 11:30 – 12:30.

Quality of life/caregiver burden in movement disorders
217 Individual Therapeutic Singing Protocol (ITSP) to improve of the vocal quality and alleviate of the depression in Parkinson’s disease: Case series Eun Young Han, Hyun Ju Chong, Kyoung-Gyu Choi, Ji Young Yun (Seoul, Korea)

Restless legs syndrome
218 Withdrawn by author
219 Impaired vascular endothelial function in patients with restless legs syndrome: A new aspect of the vascular pathophysiology Jung Han Yoon, Min Seung Kim, Seung Yan Koh (Suwon-si, Korea)
220 Restless bladder in an elderly woman: an unusual variant of restless legs syndrome Keisuke Suzuki, Masayuki Miyamoto, Tomoyuki Uchiyama, Tomoyuki Miyamoto, Koichi Hirata (Tochigi, Japan)

Spasticity
221 Meta-Analysis on botulinum toxin as early intervention for upper and lower limb spasticity following acute stroke and acquired severe brain injury to improve hypertonicity, disability, function and pain Fran Efendy, Raymond Rosales, Arlene Ng (Quezon City, Philippines)
222 Passive ROM rehabilitation immediately following botulinum toxin injection improves outcome in post-stroke spasticity Toshiaki Takeuchi (Tokusima City, Japan)
223 Hereditary spastic paraplegia in a Filipino family: A case report Paula Ruth Siongco (Manila, Philippines)

Surgical Therapy: Other Movement Disorders
224 Eighty-four months outcome of the first Japanese case of X-linked dystonia-parkinsonism (XDP: DYT-3 ‘Lubag’) improved by bilateral GPi DBS Katsuo Kimura, Fusako Yokochi, Ryoichi Okiyama, Takashi Kawasaki, Koichi Hamada, Hirokazu Iwamuro, Makoto Taniguchi (Fujisawa, Japan)
225 Bilateral globus pallidus stimulation for Huntington’s disease: a case report Jie Ren, Guoming Luan (Beijing, Peoples Republic of China)
Abstract Listing by Topic
Posters 117 – 233 will be presented on Sunday, March 13, 2016 from 11:30 – 12:30.

Tremor

226 Essential tremor in patients with Parkinson’s disease
Kateryna Kurako (Davie, FL, USA)

227 Withdrawn by author

228 Study on association between physical and genetics role in essential tremor - A case control study
Kovendan Kalimuthu, R. Chandirasekar, Murugan Kadarkarai, Vincent Savarir (Coimbatore, India)

229 Cardiovascular autonomic dysfunctions in essential tremor
Joong-Seok Kim, In-Uk Song, Jeong Wook Park (Seoul, Korea)

230 Effect of zonisamide on post-traumatic Holmes’ tremor
Satoko Sekimoto, Genko Oyama, Nana Izawa, Sinichi Ueno, Asuka Nakajima, Yasushi Shimo, Asuka Nakajima, Madoka Nakajima, Atsushi Umemura, Hajime Arai, Nobutaka Hattori (Tokyo, Japan)

Wilson’s disease, storage and metabolic movement disorders

231 Withdrawn by author

232 Side-effects of DMPS (Unithiol) infusion on the patients with Wilson disease
Xiao-Ping Wang, Hui Liu (Shanghai, Peoples Republic of China)

233 Wilson disease: a review and a case series
Mishelle Imperial, Lillian Lee (Banata, San Mateo Rizd, Philippines)
Late-Breaking Abstracts

Saturday, March 12, 2016
Poster Session: 11:30-12:30
Poster Viewing: 8:00-18:00
Location: Marriott Grand Ballroom, Ground Floor Foyer

LBA1 Non-motor symptoms profiles between Indian patients with Parkinson’s disease in West Bengal, India and White Caucasians in Europe
Anna Sauerbier, Hrishikesh Kumar, Rebecca Banerjee, Marium Umme Kulsum, Alexandra Rizos, Lauren Perkins, Theresa Chiwera, Dhaval Trivedi, Anne Martin, Miriam Parry, K Ray Chaudhuri (London, United Kingdom)

LBA2 Stress precedes hemifacial spasm: A retrospective study in multi-ethnic Penang, Malaysia
Kenny Tan, Gaik Bee Eow, Han Bing Chow, Chun Fai Cheah, Yuen Kang Chia, Jyh Yung Hor, Ruban Kanesalingam, Md Hanip Rafia, P.E. Samuel Easaw, Azman Ali Raymond, Thien Thien Lim (Penang, Malaysia)

LBA3 Genomic study and subsequent in silico drug discovery for Parkinson’s disease
Wataru Satake, Takeshi Uenaka, Cha Pei Chiang, Yukinori Okada, Kenichi Kashihara, Shigeo Murayama, Kazuko Hasegawa, Hideki Mochizuki, Atsushi Takeda, Mitsutoshi Yamamoto, Miho Murata, Nobutaka Hattori, Tatsushi Toda (Kobe, Japan)

LBA4 The effect of expiratory muscle strength training in Cantonese speaking Parkinson’s disease patients: A pilot study
Tiksang Eric Tong, Manwa Lawrence Ng, Yan Nan (Hong Kong)

LBA5 Design, synthesis and anticonvulsant activity of 1, 3, 5 -triazin-2-imine/thione incorporated pyridazines
Ravinesh Mishra, Anees A. Siddiqui, Asif Husain, Mohd Rashid, Sweta Bhardwaj (New Delhi, India)

LBA6 JPDA (Japan Parkinson’s Disease Association)
Yoshiji Matsumoto (Japan)

LBA7 Slower deterioration of non-motor symptoms and quality of life in LRRK2 protective variant carriers with Parkinson’s disease
Xiao Deng, Bin Xiao, Hui-Hua Li, Kumar M. Prakash, Yu-Lin Ng, Yew-Long Lo, Eng-King Tan (Singapore)

LBA8 Profile of Japanese encephalitis and autoimmune encephalitis patients in an 18-month period admitted in a tertiary hospital setting
Madelyn P. Pascual, Lillian V. Lee, Marilyn H. Ortiz (Philippines)

LBA9 Assessment of sleep spindle density among genetically positive spinocerebellar ataxias type 1, 2 and 3 patients: A comparative study
Ragasudha Botta, Seshagiri Doniparthi, Arun Sasidharan, Ravi Yadav, Pramod Pal, Sanjeev Jain, Bindu M. Kutty (Bengaluru, India)

LBA10 Neural underpinnings for the freezing of gait in PD: Diffusion tensor and resting state functional MRI study
Masahito Mihara, Hiroaki Fujimoto, Hironori Otomune, Yoshiyuki Watanabe, Noriaki Hattori, Hideki Mochizuki (Bengaluru, India)

LBA11 Chronic cerebral hypoperfusion accelerates cognitive dysfunction and microvascular impairment in the PTP mouse model of Parkinson’s disease
Hongmei Tang, Ruiming Zhu, Liang Gao, Kun Nie, Shujun Feng, Zhenpeng Duan, Youwen Zhang, Xin Zhao, Linmin Wang, Jiehao Zhao, Zhiheng Huang, Yuhu Zhang, Lijuan Wang (Guangzhou, China)

LBA12 Effect of single task training and dual task training on balance in individuals with Idiopathic Parkinson’s disease
Vaithiamanithi Perumal

LBA13 Asymmetric and upper body parkinsonism in patients with idiopathic normal-pressure hydrocephalus
Jinsung Park, Pan-Woo Ko, Kyunghun Kang, Ho-Won Lee (Daegu, Korea)

LBA14 Evaluation of TENM4 association with essential tremor in Singapore Chinese population
Yin Xia Chao, Ebonne Yu Lin Ng, Fiona Setiawan, Kandiah Nagaendran, Yuen Yih, Mei Sian Chong, Prakash Kumar, Louis Chew Seng Tan, Wing Lok Au, Yi Zhao, Zhi Dong Zhou, Murni Tio, Ratnapogal Pavanni, Eng King Tan (Singapore)

LBA15 Rapid eye movement sleep behavior disorder symptoms correlate with domains of cognitive impairment in Parkinson’s disease
Jin-Ru Zhang, Jing Chen, Zi-Jiao Yang, Hui-Jun Zhang, Yun-Ting Fu, Yun Shen, Pei-Cheng He, Cheng-jie Mao, Chun-Feng Liu (Suzhou, China)
Exhibit Area Floor Plans

Executive Rooms 7 and 9
Acknowledgement of Support

The International Parkinson and Movement Disorder Society – Asian and Oceanian Section (MDS-AOS) wishes to acknowledge and thank the following companies for their support:

**Platinum**

- Ipsen
- Lundbeck
- Medtronic

**Gold**

- Abbvie
- Novartis
- UCB
To better fulfill its global mission of advancing the neurological sciences as they relate to the field of Movement Disorders, MDS is continually expanding its educational portfolio. This growing portfolio offers an increasing variety of high caliber continuing medical education and continuing professional development opportunities in movement disorders. For more information about the opportunities listed in this section, please visit www.movementdisorders.org/MDS/Education.htm or e-mail education@movementdisorders.org.

Outreach Education Programs

Developing World Education Program (DWEP)
MDS recognizes that some countries do not have access to trained Movement Disorder Specialists and are restricted by size and/or resources from establishing a training program. Therefore, the Developing World Education Program is designed to address the needs of those countries and build rapport with local area societies that have no existing relationship with MDS.

DWEP’s are intended to support three course formats: a stand-alone course, courses joined with other local/regional meetings, and a series of courses over an extended timeframe.

Ambassador Program
This program supports the travel of one or two international experts who are MDS members to an underserved area for the purposes of education and intellectual exchange.

The MDS Ambassador Program supports members as keynote/plenary speakers at a non-MDS sponsored regional or national meeting in a disadvantaged country.

Sponsored speakers/faculty will work with the Ambassador Program host to develop material that is relevant and comprehensible to participants and meets the specified learning objectives of the meeting.

Visiting Professor Program
This program supports the travel of one or two international experts who are MDS members to an underserved area for the purposes of education and intellectual exchange.

The MDS Visiting Professor Program supports members in conducting teaching seminars or giving grand-rounds in local hospitals, and/or providing input for further development in the field of movement disorders in an underserved country.

Virtual Professor Program
This program supports the virtual attendance of one or two international experts to an area of need that does not allow the physical attendance of such experts (i.e. countries on the U.S. travel warnings list or hard to travel to regions).

Sponsored speakers will develop materials relevant and comprehensible to participants and deliver these materials virtually using a webinar software.

Parkinson and Movement Disorders Curriculum
The Parkinson and Movement Disorders Curriculum provides an overview of movement disorders and a clinical approach to the evaluation and management of common movement disorders. This curriculum is specially developed for trainees, internists, general neurologists and other clinicians interested in acquiring a basic understanding of movement disorders.
Education Information

New E-Learning Portal
In alignment with the mission of MDS to advance the education of medical professionals worldwide, improve diagnosis and treatment, and encourage research in Parkinson’s disease and all other movement disorders, The society now offers a full spectrum of e-learning educational opportunities to members and non-members alike.

These MDS e-learning courses will now be presented using a new custom Learning Management System (LMS) software. This new system creates a single portal that houses all MDS educational activities, and allows all users to review their progress, retrieve certificates and keep track of their e-learning CME credits. Questions regarding the new e-learning portal and virtual educational opportunities, can be sent via e-mail to e-learning@movementdisorders.org.

Online CME Activities
All of the following CME activities are offered through the MDS e-learning portal:

Journal CME
These modules offer CME credit for the review of Movement Disorders Journal articles. MDS is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide certified continuing medical education for physicians. MDS designates these educational activities for a maximum of 1.0 AMA PRA Category 1 Credit™ each. Upon successful completion of a Journal CME activity, users will receive a CME certificate documenting their achievement.

Coffee Break CME
This program was designed to provide continuing education critical to providing the best care possible. Scientific content is presented in a modular format, where each module is focused on a single topic which can be completed in a short period of time, providing the clinician with updated information relevant to their practice. Both standard approaches and new advances are highlighted.

The scope of this program includes modules on: parkinsonism, tremor, dystonia, chorea, and other topics as identified. After users have registered for a module, they are able to log in to the site as many times as needed to view all the material. At the beginning and completion of each module, participants are asked content-related questions to gauge their learning.

MDS is accredited by the ACCME to certify 2.0 AMA PRA Category 1 Credit™ for each module. Upon successful completion of a Coffee Break CME activity, users will receive a CME certificate documenting their achievement.

Device Aided Medical Therapies
Device-Aided Medical Therapies in Parkinson’s Disease is an online course series designed by a panel of worldwide specialists around the main practical issues involved with device-aided treatments of Parkinson’s disease. Each module takes approximately one hour to complete. This course series, provided as ten separate modules, addresses issues such as identifying patients who may or may not benefit from the treatment, recognizing the titration and the monitoring of clinical response, recognizing the main complications and managing them, and comparing these treatments with conventional oral dopaminergic therapies, as well as against each other.

MDS designates these educational activities for a maximum of 1.0 AMA PRA Category 1 Credit™ each. Upon successful completion of a Device-Aided Medical Therapy activity, users will receive a CME certificate documenting their achievement.

Other Online Education Resources
MDS provides a variety of online educational activities in addition to streaming video and CME programming. The following educational tools are available on the MDS website.

Fundamentals of Movement Disorders
The goal of this new video series is to provide residents an overview of movement disorders with a clinical approach to the evaluation and management of common disorders. The 31 presentations, delivered by expert physicians from around the world, cover the fundamental topics in movement disorders to help provide a base knowledge for residents. All Fundamentals of Movement Disorders presentations are offered through the MDS e-learning portal.

MDS Video Library
This members only library consists of video supplements from the Movement Disorders Journal since 1986. Videos can be searched by keyword, author, volume and issue or a combination of these fields.
2016 MDS Education Calendar

Dates and locations are subject to change. For a complete up-to-date list of courses, visit www.movementdisorders.org/MDS/education.htm
20th International Congress of Parkinson’s Disease and Movement Disorders
JUNE 19-23, 2016 • BERLIN, GERMANY

Come Join Us
www.mdscongress2016.org

IMPORTANT DATES
April 15, 2016 Early Registration Deadline
May 18, 2016 Final Pre-Registration Deadline
Challenges, Trends and Future Perspectives in Parkinson’s Disease and Dementia

A Novartis-sponsored Symposium:
5th Asian and Oceanian Parkinson’s Disease and Movement Disorders Congress

Friday 11th, March 2016 • 13:15 – 14:15 • Marriott Grand Ballroom Hotel • Manila Philippines
A corporate satellite symposium supported by AbbVie at the 5th Asian and Oceanian Parkinson’s Disease and Movement Disorders Congress
11–13 March, 2016 • Manila, Philippines

ABBVIE INVITES YOU TO JOIN A SYMPOSIUM AT THE AOPMC-MDS

Friday, 11 March 2016 • 4:00pm–5:00pm
Grand Ballroom, Marriott Hotel
Manila, Philippines

At this educational symposium, the expert panel will discuss the advanced Parkinson’s Disease landscape; from natural progression to latest evidence for therapeutic options, including patient profile considerations in the clinical setting.

Advanced Parkinson’s Disease – Natural Progression, Emerging Data and Patient Profile Considerations in the Clinical Setting

Introduction
Prof Carolyn Sue – Royal North Shore Hospital, Australia

Advanced PD Landscape – Incidence, definition & patient considerations including emerging data for advanced PD treatment options
Assoc Prof Tom Kimber – Royal Adelaide Hospital, Australia

Which patient for which therapy and when? Is there a clear patient profile for the different advanced PD therapies?
Dr Andrew Evans – Royal Melbourne Hospital, Australia

Discussion and audience questions
How can we empower our Parkinson’s disease patients and optimise clinical outcomes?

Friday 11th March 2016 | 17:15–18:15

Chairperson – Dr. Andrew Evans (Royal Melbourne Hospital, Melbourne, Australia)

Patients & neurologists – a partnership for success

Dr. Andrew Evans
Royal Melbourne Hospital, Melbourne, Australia

Integrating patient concerns into disease management

Prof. Lim Shen-Yang
Department of Medicine, University of Malaya, Kuala Lumpur, Malaysia

Joint decisions on treating nocturnal symptoms – what do patients need to know?

Prof. Roongroj Bhidayasiri
Chulalongkorn Centre of Excellence for Parkinson’s Disease and Related Disorders, Chulalongkorn University Hospital, Bangkok, Thailand

Christer, living with Parkinson’s disease

Inspired by patients. Driven by science. A Promise for Life
Regain control of Parkinson’s disease symptoms with APO-go
For Patients with Parkinson’s Disease

FP Pharmaceutical Corp. is pleased to be a supporter of the 5th Asian and Oceanian Parkinson’s Disease and Movement Disorders Congress

Manila, Philippines
March 11 - 13, 2016

We dedicate ourselves to distribution of Selegiline in Japan.

FP Pharmaceutical Corp.
1-3-40 Nishiotsuka, Matsubara, Osaka,
580-0011 JAPAN
Certifies that

has attended the 5th Asian and Oceanian Parkinson’s Disease and Movement Disorders Congress on March 11-13, 2016 at the Marriott Grand Ballroom located in Manila, Philippines.

Raymond Rosales
Chair
5th AOPMC Scientific Program Committee

Nobuaki Hattori
Chair
5th AOPMC Oversight Committee

Oscar Gershonik
President
International Parkinson and Movement Disorder Society, 2015-2017
Asian perspectives on recognition and treatment of levodopa-induced motor complications in Parkinson’s disease

Chaired by Roland Dominic Jamora, Philippines

Date: Saturday 12th March 2016
Time: 13:00–14:00
Venue: Grand Ballroom, Rooms 1+2, 2nd Floor

Programme

Chairman’s introduction

Clinical management of Parkinson’s disease in Asia
– recent developments in the use of levodopa

Levodopa-related motor complications in PD
– mechanisms and treatment approaches

Panel discussion

Roland Dominic Jamora,
Philippines

Piu Chan,
China

Werner Poewe,
Austria

Led by Chairman

Satellite symposium at the 5th Asian and Oceanian Parkinson’s Disease and Movement Disorders Congress
11th–13th March 2016
Marriott Hotel Manila, Manila, Philippines

Corporate Satellite Symposium supported by H. Lundbeck A/S
MEDTRONIC ANNOUNCES
THE WORLD’S FIRST AND ONLY
FULL-BODY MR CONDITIONAL
DBS SYSTEMS*

Damian, Implanted with
Medtronic Activa® PC

* Medtronic DBS systems are MR Conditional, indicating they are safe in the MR environment as long as certain conditions are met. Read and fully understand the MRI Guidelines for Medtronic deep brain stimulation systems before conducting the MRI examination. Go to www.medtronic.com/mri or contact Medtronic at 1-800-707-0913 for a copy. Also review current MRI manufacturer labeling before conducting the MRI.

Important safety information is available at the Medtronic exhibit booth.